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ABSTRACT	  Molecular	  Mechanisms	  Controlling	  Synaptic	  Vesicle	  Fusion	  Daniel	  Radoff	  	   SNARE	  proteins	  are	  the	  engines	  that	  drive	  membrane	  fusion	  throughout	  the	  cell.	  	  They	  provide	  this	  energy	  by	  zippering	  up	  into	  a	  parallel	  four	  helix	  bundle	  in	  a	  thermodynamically	  favored	  process.	  Because	  the	  zippering	  of	  SNAREs	  is	  spontaneous,	  fusion	  events	  occur	  immediately	  upon	  a	  vesicle	  interacting	  with	  its	  target	  membrane.	  But,	  in	  certain	  circumstances,	  such	  as	  in	  synaptic	  vesicles,	  spontaneous	  fusion	  is	  not	  desired,	  so	  a	  clamp	  protein	  is	  necessary	  to	  prevent	  this	  fusion	  until	  signaled	  to	  do	  otherwise.	  	  In	  synapses,	  this	  protein	  is	  called	  Complexin	  and	  a	  second	  protein,	  called	  Synaptotagmin,	  releases	  the	  clamp	  upon	  a	  rapid	  influx	  of	  calcium,	  the	  hallmark	  of	  an	  action	  potential.	  	  How	  Complexin	  clamps	  is	  a	  subject	  of	  great	  interest	  in	  the	  field,	  and	  an	  area	  of	  active	  research.	  	   What	  is	  known	  is	  that	  a	  so-­‐called	  Accessory	  helix	  (residues	  28-­‐47)	  is	  responsible	  for	  clamping,	  while	  another,	  Central	  Helix	  (reisudes	  48-­‐70)	  is	  responsible	  for	  physically	  binding	  to	  the	  helix.	  	  A	  recently	  solved	  crystal	  structure	  revealed	  how	  CPX	  might	  behave	  before	  the	  SNAREs	  fully	  zipper,	  namely	  that	  the	  accessory	  helix	  extends	  away	  from	  the	  SNAREs	  at	  a	  45°	  angle.	  	  But,	  because	  of	  the	  packing	  of	  the	  crystal,	  it	  is	  entirely	  possible	  that	  the	  crystal	  is	  an	  artifact	  of	  packing,	  and/or	  truncation.
In	  this	  thesis,	  my	  work	  first	  validates	  the	  crystal	  structure,	  using	  a	  FRET	  pair	  I	  developed	  for	  this	  purpose.	  	  I	  establish	  that	  the	  angled-­‐out	  positioning	  of	  the	  accessory	  helix	  does,	  in	  fact,	  occur	  in	  solution,	  and	  is	  not	  due	  to	  crystal	  packing	  or	  the	  truncation	  of	  the	  VAMP2	  (the	  neuronal	  vesicle-­‐associated	  SNARE),	  but	  rather	  is	  due	  to	  the	  fact	  that	  its	  C-­‐terminus	  is	  not	  present.	  	  I	  describe	  a	  mechanism	  by	  which	  Complexin	  can	  clamp.	  	  Further,	  I	  demonstrate	  that	  the	  residues	  in	  VAMP2	  which	  are	  responsible	  for	  the	  switch	  from	  the	  “open”	  to	  the	  “closed”	  conformation	  are	  a	  patch	  of	  asparatates	  in	  VAMP2	  (residues	  64,	  65,	  an	  68).	  	  I	  also	  establish	  that	  these	  three	  aspartates	  are	  responsible	  for	  the	  release	  of	  the	  clamp	  and	  that	  without	  them,	  Complexin	  cannot	  be	  brought	  into	  the	  angled-­‐in	  configuration.	  I	  propose	  a	  model	  for	  how	  the	  clamp	  might	  be	  released	  by	  Synaptotagmin.	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Neurons are responsible for transmitting sensory information in all animals from 
worms to humans.  Dendrites receive a stimulus from a preceding cell, in the form of a 
neurotransmitter, which opens transmitter-gated ion channels, allowing sodium to flow 
into the cell resulting in an electric potential difference	  [1]. This electrical signal, called 
an action potential, then proceeds down the length of the neuron by opening potential-
gated ion channels present along the plasma membrane, although the cell body and along 
the axon to the terminal branches, where it finally reaches the presynaptic bulb, a small 
reservoir before the synapse, the space between two neighboring neurons. At the 
presynaptic bulb, when the electrical impulse depolarizes the plasma membrane, voltage-
gated Ca2+ channels open, resulting in a large increase in the local cytosolic calcium 
concentration. This triggers the release of neurotransmitters from the presynaptic cell, 
where they are stored in vesicles, which are docked in the presynaptic bulb and ready to 
be released across the synapse to the postsynaptic cell’s dendrites, where they bind to 
transmitter-gated ion channels, and allow the electrical signal to further propagate to its 
ultimate destination, Figure 1	  [1].	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Figure	  1:	  A	  diagram	  of	  two	  nerve	  cells	  with	  selected	  regions	  of	  the	  cell	  labeled	  to	  accentuate	  the	  regions	  involved	  in	  nervous	  signal	  transmission	  from	  one	  cell	  to	  a	  neighbor.	  	  The	  action	  potential	  proceeds	  from	  the	  dendrites,	  through	  the	  cell	  body,	  and	  along	  the	  axon	  before	  ultimately	  reading	  the	  terminal	  branches	  of	  the	  presynaptic	  bulb.	  	  Upon	  arrival	  of	  this	  electrical	  signal,	  calcium	  enters	  the	  presynaptic	  bulb	  and	  the	  vesicles,	  which	  had	  previously	  been	  building	  up	  in	  concentration,	  are	  rapidly	  and	  synchronously	  released.	  	  INSET:	  an	  EM	  micrograph	  from	  [7]	  showing	  the	  synapse.	  	  In	  the	  presynaptic	  bulb,	  vesicles	  have	  accumulated,	  awaiting	  an	  action	  potential,	  which	  will	  trigger	  their	  fusion	  to	  the	  neighboring	  cell’s	  dendrite.	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The mechanisms of these processes are starting to be more fully understood via 
both in vivo and in vitro experiments, but significant controversy still remains in some of 
the details, especially in the later stages of signal transduction.  Specifically, questions 
remain as to how the action potential is able to cause synchronous release of vesicles on 
the order of less than one millisecond [2].  To understand the problem more completely, 
there is value in understanding the molecular mechanisms of cellular trafficking.   
Cellular trafficking follows a relatively straightforward pathway	  [3-5].  Various 
molecules (like glutamate, hormones, and neuropeptides, [1]) are created in the 
endoplasmic reticulum or other parts of the cell and shuttled through the Golgi where 
they are enclosed in secretory vesicles which then bud from the trans-Golgi network and 
are transported along microtubules to their target membranes (Reviewed in	  [6], Figure 2).  
For neurotransmitters, this target is a region near the plasma membrane of the presynaptic 
cell called the presynaptic bulb, where they are observed to remain, primed and ready for 
fusion until the action potential signals their release, Figure 1, inset [7].  The action 
potential is an electrical signal which initiates fast fusion of the vesicles and allows the 
release of the vesicles’ contents.  This is in stark contrast with vesicle-target membrane in 
other parts of the cell [8].  In those cases, fusion is not arrested, awaiting an external 
signal, but rather rather the fusion process occurs asynchronously, whenever the vesicle 
arrives at the target membrane	  [9]. Understanding the mechanism of how vesicles fuse to 
target membranes is of extreme interest, as is understanding how synaptic vesicles 
specifically are able to achieve such precise temporal control over the fusion process 
unlike their counterparts in the other parts of the cell.  
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Figure	  2:	  A	  diagram	  of	  cellular	  trafficking	  from	  [4].	  	  Proteins	  and	  peptides	  are	  created	  in	  the	  ER,	  where	  they	  are	  enclosed	  in	  vesicles	  and	  shuttled	  to	  the	  Golgi,	  where	  these	  proteins	  are	  post-­‐translationally	  modified	  and	  sorted.	  	  From	  the	  Golgi,	  the	  proteins	  can	  be	  sent	  to	  various	  cellular	  compartments	  like	  the	  endosome	  or	  the	  lysosome,	  or	  they	  can	  be	  exocytosed.	  	  It	  is	  the	  regulated	  exocytosis	  process	  that	  this	  thesis	  focuses	  on.	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VESICLE FUSION TO TARGET MEMBRANES 	  	  
The question of phospholipid bilayer fusion has been the subject of numerous 
biophysical and biochemical studies (for reviews, see [9-12],	  in which many aspects have 
been examined from the energetics	  [10,	  13-­‐19] and the mechanics [11, 18, 20] of fusion 
to the proteins responsible for providing the forces necessary to achieve such a 
technically difficult task so rapidly.    
To fully appreciate the scope of this problem, it is useful to briefly consider the 
energy-intensive steps that have to be overcome to enable two membranes to fuse [10]. 
Before two membranes can fuse, the vesicle must be brought into close proximity with 
the target membrane, interstitial water molecules and proteins must be removed, from the 
interface between the two membranes and the repulsive forces between the charged 
headgroups on the lipid molecules must be overcome [9].  Further, most models of fusion 
have the two membranes locally puckering just before fusion occurs, as this state is more 
fusogenic due to the membrane deformation. The energy for such curvature deformations 
during fusion-pore formation and the ones that follow in the subsequent expansion of the 
fusion pore must also be overcome.  Finally, and perhaps most importantly, the physical 
rupture of the outer leaflets and the inner leaflets of the membrane requires a significant 
amount of energy to occur.  This process is depicted in Figure 3.  The role of fusion 
proteins is to provide the energy that these processes require to allow fusion to occur. The 
energetics will be discussed more in depth later, after I fully introduce the proteins 
involved in fusion.   
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Figure	  3:	  The	  steps	  involved	  in	  membrane	  fusion,	  from	  [95].	  	  First,	  a	  vesicle	  is	  brought	  into	  close	  proximity	  to	  its	  target	  membrane	  by	  tethering	  factors.	  	  Then,	  as	  the	  interstitial	  proteins	  and	  water	  molecules	  are	  removed,	  SNAREs	  bring	  the	  membranes	  even	  closer	  together	  and	  provide	  the	  energy	  required	  for	  fusion.	  	  Fusion	  can	  be	  paused	  at	  this	  stage	  in	  exocytosis	  by	  certain	  regulatory	  factors	  like	  the	  Complexin	  family,	  which	  are	  discussed	  later.	  	  The	  two	  membranes	  then	  pucker	  towards	  each	  other,	  lowering	  the	  energy	  barrier	  to	  fusion.	  	  First,	  hemifusion,	  in	  which	  only	  the	  outer	  leaflets	  fuse,	  and	  then	  full	  fusion,	  in	  which	  both	  the	  outer	  and	  inner	  leaflets	  fuse,	  occurs.	  	  This	  is	  then	  either	  followed	  by	  quick	  resealing	  of	  the	  nascent	  fusion	  pore	  (called	  kiss-­‐and-­‐run)	  or	  rapid	  opening	  of	  the	  pore,	  and	  ultimately	  collapse	  of	  the	  vesicle	  into	  the	  target	  membrane.	  
	  
 	   	   	   	  
7 
STEPS OF MEMBRANE FUSION 	  
Through biochemical evidence [9, 21], the following picture has emerged of 
how membrane fusion must occur, Figure 3. Briefly, the vesicle is first captured by so-
called tethering factors like the exocyst, COG, GARP, or Dsl1 complexes (reviewed in 
[22]) located on the target membrane which are thought to bring the vesicle in close 
proximity with the membrane and position the membranes for optimal fusion.  Then, 
resident proteins called SNAREs on both the target membrane (called t-SNAREs) and the 
vesicle membrane (called v-SNAREs) begin to interact with each other via their N-
termini.  These interactions lead to partial structuring of the SNAREs’ N-termini into α 
helices.  In the majority of fusion events in the cell, the SNAREs proceed to interact very 
quickly to form an extremely stable four helix bundle [23], and this interaction is thought 
to provide the energy for fusion [24, 25].  It certainly brings the vesicle even closer to the 
target membrane.  Through some process, which may just be thermal fluctuations, but 
which might be protein-mediated, there is a local puckering of the membranes, which 
serves to ease fusion and allow for a stage called hemifusion in which only the outer 
leaflets of the membrane fuse to occur. This is followed by full fusion, where the inner 
leaflets of the membrane fuse too.  The nascent fusion pore can then either reclose, in a 
phenomenon called kiss-and-run [26], or it can enlarge resulting in full release of the 
vesicles’ contents.  
Afterwards, the SNARE protein four-helix bundle is recycled to its individual 
proteins via an ATPase called NSF and its binding partner αSNAP to be ready for 
subsequent rounds of transport [26, 27].  Interaction of a hexamer of NSF and three 
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αSNAPs with the cis-SNARE complex leads to the formation of a transient 20S 
complex[28, 29].  ATP hydrolysis by NSF leads to the disassembly of this 20S complex 
as well as of the cis-SNARE complex.  The freed v-SNAREs can then be recycled back 
to the donor compartment by retrograde vesicle transport, while the t-SNAREs can be 
reorganized into functional t-SNAREs, ready for the next round of vesicle docking and 
fusion [30]. 
HOW DO VESICLES FIND THE CORRECT MEMBRANE? 	  
Fusion can occur at various membranes throughout the cell. To answer the 
question of how vesicles fuse in a specific manner, a more in depth understanding of the 
responsible SNARE proteins must be undertaken. SNARE proteins belong to a class of 
small (100-300 amino acids), and mostly unstructured [31] proteins, which, upon contact 
with relevant cognate partners, progressively gain alpha helical structure from their N- to 
C-termini to make parallel four helix bundles in a process referred to as “zippering” [32].  
According to the SNARE hypothesis [33], only certain pairings of v- and t-SNAREs form 
productive four helix bundles, helping to provide the specificity for the fusion 
process.  The examples in a mammalian cell of known cognate partners and where they 
occur are shown in Figure 4 [34].  Because the zippering process is thermodynamically 
favored [18], it can provide some or all of the energy to overcome the barrier to 
fusion.  In theory, each helix in the four helix bundle can be provided by a different 
protein forming a quaternary complex; however, although in several cases, like in the 
synaptic SNAREs and SNAP25, one protein contributes two helices instead of one, 
making a ternary complex [34].  
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Figure	  4:	  A	  diagram	  of	  the	  known	  SNARE	  complexes	  for	  many	  of	  the	  cellular	  trafficking	  events	  in	  a	  cell	  from	  [34].	  	  The	  vesicle-­‐associated	  SNARE	  is	  labeled	  in	  red.	  	  The	  main	  focus	  of	  this	  thesis,	  the	  synaptic	  vesicle	  is	  depicted	  in	  the	  top	  middle	  of	  the	  diagram	  as	  SV,	  and	  utilizes	  the	  SNAREs	  Syntaxin1	  (Syn1),	  SNAP25,	  and	  VAMP2.	  	  Other	  abbreviations	  used	  in	  this	  figure	  are	  EGTC	  (ER	  Golgi	  Transport	  Container)	  and	  ERES	  (ER	  Exit	  Site). 
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STRUCTURE AND FUNCTION OF SNARES 	  
Humans have 36 members of the SNARE protein family [34-36], and all 
members of this family either have transmembrane domains or palmitoylation or 
farnesylation motifs to tether them to the membranes [34]. The phylogenetic tree of the 
36 SNAREs is shown in Figure 5 [34]. The majority of any individual SNARE protein, 
be it a v- or a t-SNARE, is expressed on the cytoplasmic side of the membrane [34]. For 
those examples which have transmembrane domains, there is often a short extracellular 
or intralumenal tail for t- or v-SNAREs, respectively. 
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Figure	  5:	  A	  phylogenetic	  tree	  of	  the	  SNAREs,	  adapted	  from	  [34].	  	  SNARE	  four	  helix	  bundles	  form	  by	  using	  one	  helix	  from	  each	  of	  the	  four	  main	  brances	  of	  SNAREs.	  	  All	  but	  three	  SNAREs	  only	  possess	  one	  helix;	  those	  three	  occur	  twice	  on	  this	  diagram,	  once	  for	  each	  helix.	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All SNARE proteins consist of a simple domain structure, Figure 6.  The most 
characteristic domain of SNARE proteins is the evolutionarily conserved “SNARE 
motif,” a stretch of between 60 and 70 amino acids arranged in heptad repeats, which 
form the basis for the alpha helical interaction domains of the SNARE four helix bundle. 
[27, 37-40] These are the domains that are responsible for the “zippering” from the N- to 
the C-terminus.  This motif is characterized by 16 layers of interacting hydrophobic side 
chains which form the binding interface that keep the coiled-coil together [41]; all 
hydrophobic that is, except for a central “0” layer which contains three highly conserved 
glutamine residues and one highly conserved arginine residue[42].  The seven 
hydrophobic layers located N-terminal to the “0” layer are denoted as “-7” to “-1,” while 
the eight layers C-terminal to the “0” layer are called “+1” through “+8.” Most SNAREs 
(33/36 in humans) contain only one SNARE motif; the other three, like the neuronal 
SNAP25, contain two SNARE motifs, and are the proteins mentioned above which are 
capable of contributing two alpha helices to the four helix bundle.  In 1998, Sutton et al. 
solved a crystal structure of the neuronal synaptic SNAREs’ SNARE motifs[37].  In the 
crystal structure, Figure 7, the SNARE domains form a complex which is 12 nm long and 
between 1.3 and 1.5 nm in diameter[37]. 
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Figure	  6:	  The	  generic	  domain	  structure	  of	  the	  SNAREs.	  	  The	  cylindrical	  domains	  represent	  alpha	  helices,	  while	  the	  zig-­‐zag	  structures	  represent	  the	  SNAREs	  which	  are	  tethered	  to	  the	  membrane	  not	  by	  transmembrane	  domains,	  but	  rather	  by	  palmitoylation	  or	  farnesylation.	  	  The	  domains	  surrounded	  by	  dashed	  lines	  are	  not	  present	  in	  all	  members	  of	  each	  class	  of	  SNARE.	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Figure	  7:	  The	  SNARE	  domains	  of	  the	  neuronal	  synaptic	  four	  helix	  bundle	  [37].	  	  The	  t-­‐SNAREs	  are	  in	  yellow	  (Syntaxin1)	  and	  green	  (SNAP25;	  N-­‐terminal	  helix	  is	  in	  lime;	  C-­‐terminal	  helix	  is	  in	  forest).	  	  The	  v-­‐SNARE	  (VAMP2)	  is	  in	  blue.	  	  The	  SNAREs	  are	  fully	  zippered	  into	  a	  parallel	  four	  helix	  bundle. 
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At the C-terminus, the majority (31/36 in humans) of SNAREs has a 
transmembrane domain which adjoins the SNARE motif via a short linker peptide 
[34].This transmembrane domain is required for fusion[39], and if it is disrupted, no 
fusion can occur.  In fact, even if the linker between the four helix bundle and the 
transmembrane domain is disrupted, fusion is inhibited [43, 44].  The energy of zippering 
is transmitted through these domains and they are at least partially responsible for 
ensuring membrane fusion occurs.  In addition, in vivo, for membrane fusion to occur, the 
zippering of the four helix bundle must be coupled energetically to the transmembrane 
region of the SNAREs.  The insertion of flexible linkers between the SNARE motif and 
the transmembrane region either reduces or abolishes fusion both in vitro and in vivo 
[45]. Also, replacement of the transmembrane domain by lipid anchors allows vesicle 
docking, but it prevents fusion to a large degree[46].   
Recently, a crystal structure was published of the neuronal SNAREs including 
their transmembrane domains[47], Figure 8, which showed that even in the membranes, 
in the cis-SNARE complex, the helicity is maintained throughout.  This gives further 
credence to the necessity for helicity of the SNAREs in the fusion process. Because the 
transmembrane domains physically interact with both the inner and the outer leaflets [47] 
of the membrane, it is throught the interaction between the transmembrane regions of 
both v- and t-SNAREs may contribute to the transition from hemifusion to full fusion.  
  
 	   	   	   	  
16 
	  
Figure	  8:	  The	  SNARE	  domains	  of	  the	  neuronal	  synaptic	  four	  helix	  bundle,	  extended	  to	  include	  their	  transmembrane	  domains	  from	  [47].	  	  Note	  that	  SNAP25	  does	  not	  extend	  into	  the	  membranes.	  The	  t-­‐SNAREs	  are	  in	  yellow	  (Syntaxin1)	  and	  green	  (SNAP25;	  N-­‐terminal	  helix	  is	  in	  lime;	  C-­‐terminal	  helix	  is	  in	  forest).	  	  The	  v-­‐SNARE	  (VAMP2)	  is	  in	  blue.	  	  This	  crystal	  structure	  suggests	  that	  the	  transmembrane	  domains	  are	  helical	  throughout	  the	  membrane.	  
 	   	   	   	  
17 
  
A smaller majority (26/36 in humans) also has some sort of N-terminal domain 
[34].  The proteins without N-terminal domains are called “brevins,” and included in this 
category is the neuronal protein VAMP2, also called synaptobrevin [48], as well as 
VAMP3 [49], called cellubrevin, a protein which can substitute for VAMP2 in vivo [49, 
50]. There are a few subclasses of proteins with N-terminal domains, most of which are 
inhibitory towards four helix bundle formation.  One subclass consists of an antiparallel 
three-helix bundle, called an Habc domain. (An example of this class is the neuronal 
protein Syntaxin1 (SYN).) [51-53].  The Habc domain is connected to the SNARE motif 
by a flexible linker, and it can reversibly associate with the SNARE motif to form a four-
helix bundle known as a “closed” complex, which effectively prevents interaction of the 
protein in question with other SNAREs, rendering it incapable of forming a productive 
four-helix bundle.  Another class of N-terminal domains in the SNAREs are the longin 
domains, which form a beta-sheet surrounded by three alpha helices[54]. It appears these 
longin domains have a similar inhibitory function to Habc domains.  This “closed” 
conformation must be opened by a regulatory protein (like a member of the SM class of 
proteins including Munc18 which works on the neuronal t-SNARE syntaxin) before 
and/or during the assembly of the SNAREs	  [51,	  55,	  56]. This provides a mechanism by 
which membrane fusion pathways can be regulated at an early state in the fusion 
pathway, before the SNAREs even associate, if fusion is for some reason undesirable. 
NEURONAL SNARES 	  
Because this thesis focuses specifically on synaptic vesicle fusion, there is 
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further benefit to discuss the history of the SNAREs involved in this complex, the t-
SNAREs, SNAP25 and Syntaxin1, and the v-SNARE, VAMP2 [34, 39].These proteins 
were among the first SNAREs to be discovered because of their prevelance in the 
synapse[48, 57, 58] as well as though their interactions with other prevalent synaptic 
proteins like NSF [34, 59].  NSF (N-ethylmaleimide Sensitive Fusion protein) was 
discovered in 1988 by Rothman and colleagues[60] as a protein which rescues Golgi 
transport upon blocking by N-ethylmaleimide (NEM).  In 1990, Rothman and 
colleagues[61] discovered a class of proteins which physically interact with NSF called 
Soluble NSF Attachment Proteins (SNAPs), as a set of proteins thought to be involved 
somehow in membrane fusion.  Recall, these are the proteins responsible for disassembly 
of the SNARE complex[30]. 
VAMP2 and SNAP25 were both discovered in 1989.  VAMP2, the neuronal v-
SNARE by Elferink et al. [48] and SNAP25, one of the neuronal t-SNAREs by [57], both 
as widely expressed neuronal proteins.  VAMP2 has a transmembrane domain[48], while 
SNAP25 has a CAAX box which is post-translationally palmitoylated, tethering it to the 
membrane without a transmembrane domain [36]. Syntaxin1, the other synaptic t-
SNARE, was discovered in 1992 by Bennett et al. [58] as a 35 kDa protein that interacts 
with another prevalent synaptic vesicle-associated protein called Synaptotagmin, which is 
an important SNARE regulatory protein, and will be discussed more in depth 
later.  Rothman and colleagues [59] recognized that all of these proteins were binding 
partners of SNAPs and named them SNAP Receptors (SNAREs) in 1993 [59].  
THE SNARE FUSION PATHWAY 	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To understand the temporal control synapses have over fusion, it is vitally 
important to understand the steps involved in SNARE-mediated fusion.  The general 
consensus is that SNAREpin assembly itself occurs in a stepwise manner, starting at the 
amino-terminal, membrane-distal end of the SNARE motif and proceeding toward the 
carboxy-terminal, membrane-proximal end[35, 62-65].  Initially, the membrane-proximal 
regions are largely unstructured and are targets for regulatory components that either 
accelerate or delay SNAREpin assembly [24, 42, 65-68]. Once the N-terminal portions of 
the SNARE domains of the v- and t-SNAREs are zippered, the remainder of the t-
SNARE domains begin to form α helices, forming so-called “acceptor” complexes[24, 
39, 69, 70], ready for the v-SNARE to continue to zipper up and provide the energy 
needed for fusion.  Figure 9 shows a schematic of the steps of SNARE association. 
Another question debated in the field is how many four helix bundles, also 
known as SNAREpins, are required for fusion to occur.  In PC12 cells, at least three 
SNARE complexes seem to be required to fuse secretory granules with the plasma 
membrane [71].  And in another study, between 5 and 8 were suggested based on sterics 
of interaction.[72] Karatekin et al. showed that the number of SNAREpins required for 
fusion is between five to ten[73].  A much higher number (10-15) was predicted by 
titrating in neurotoxins into cultured neurons.[74] Though, somewhat contradictorily, it 
has been observed that only one SNARE complex is sufficient for fusion [75] via single 
molecule studies. Furthermore, the minimal number of required SNAREpins is likely 
influenced significantly by membrane curvature, the lipid/protein composition of a 
compartment, and the presence of lipid bilayer perturbing regulators [55].  That said, it is 
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generally assumed that between five and ten SNARE complexes are required for exocytic 
vesicle fusion within neuronal cells. 




Figure	  9:	  The	  steps	  of	  SNARE-­‐mediated	  fusion,	  adapted	  from	  [65].	  	  First,	  when	  the	  SNAREs	  associate,	  they	  do	  so	  via	  their	  N-­‐termini.	  	  The	  SNAREs	  then	  structure	  and	  zipper	  form	  their	  N-­‐	  to	  C-­‐termini.	  	  The	  t-­‐SNAREs	  may	  associate	  with	  each	  other	  first,	  forming	  what	  is	  called	  an	  “acceptor”	  complex,	  to	  which	  a	  v-­‐SNARE	  can	  then	  associate	  via	  its	  N-­‐terminus,	  forming	  a	  trans-­‐SNARE	  intermediate.	  	  This	  state	  proceeds	  rapidly	  to	  a	  fully	  zippered	  SNARE	  complex	  unless	  acted	  upon	  by	  a	  regulatory	  protein	  like	  Complexin.	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It has, however, been shown that different t- and v-SNARE-containing 
complexes can form in vitro.  Such different t- and v-SNARE states can exist on a 
timescale of seconds, as shown by single-molecule FRET measurements.  For example, 
Weninger et al. [76] showed that in vitro, as many as 88% of SNAREs do not form 
parallel four-helix bundles at any given time.  And that although parallel four-helix 
bundles presumably correspond to the lowest energy state [76], suggesting there must be 
folding and refolding that can occur, at least in vitro, suggesting the possibility of similar 
occurrences in vivo. 
Other in vitro single molecule experiments on both exocytic S. cerevisiae and 
synaptic SNARE complexes [24, 69, 70] have shown that SNARE complex assembly 
proceeds through a defined and partially helical t-SNARE intermediate, the formation of 
which is rate limiting.  This suggests, not surprisingly, that assembly is an ordered, 
sequential reaction rather than a random collision of four SNARE motifs[39].  Only when 
an “acceptor” t-SNARE complex, possibly lacking a v-SNARE in which the N-terminal 
ends of the t-SNARE SNARE motifs are structured is the v-SNARE able to bind with 
biologically relevant kinetics and initiate the zippering reaction. It is important to note 
that this “acceptor” complex is theoretical and has never been experimentally observed. 
Acceptor SNARE complexes lacking the v-SNARE and containing only t-
SNAREs are expected to be highly reactive, extremely transient species, explaining why 
they are notoriously difficult to characterize[39].  For example, in vitro, the neuronal 
acceptor complex quickly recruits a second syntaxin, leading to the formation of a “dead-
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end” complex, consisting of a four-helix bundle, two helices from one SNAP25, and one 
each from two different Syntaxin molecules [69]. This interaction prevents the binding of 
the v-SNARE altogether and may be responsible for the observed in vitro slow kinetics of 
core complexes. 
There has been until now, very little information regarding the existence of 
acceptor t-SNARE complexes in vivo or in intact cells[77-79].  Furthermore, upon 
recognition of the v-SNARE by the t-SNARE-acceptor complex, a trans-SNARE 
complex, in which the t-SNAREs are fully zippered while only the N-terminal SNARE 
domain of the v-SNARE is α-helical and zippered, is formed[39].  Trans-SNARE 
complexes are also extremely short-lived structures and attempts to isolate them have 
included the detergent solubilization of membranes [39], which ultimately resulted in 
their immediate conversion from partially-zippered trans- to fully-zippered cis- forms.   
The best in vivo evidence for the existence of trans-SNARE intermediates 
comes from the study of regulated neuronal exocytosis.  Because neuronal exocytosis is 
regulated at a late step just before membrane fusion, it is unlike other intracellular fusion 
events[80].  Recall that vesicles sit, docked at the plasma membrane, primed, and ready 
for fusion, but unable to fuse until the action potential signal arrives [1, 2].  In this 
circumstance, it is probable that metastable trans-SNARE complexes exist [80] and are 
responsible for this docked state.  Evidence for this is provided by the observation that, in 
chromaffin cells, kinetically distinct pools of vesicles, potentially representing sequential 
steps along the exocytosis pathway, can be distinguished by electrophysiological methods 
like patch clamp [39]. SNARE assembly has been perturbed in these cells by various 
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means, including the use of SNARE-cleaving toxins, anti-SNARE antibodies, and the 
expression of SNAP25 and VAMP variants in knockout cells[80, 81], and exocytosis is 
reduced when using manipulations that are expected to impair the zippering of 
SNAREs.  The data are best explained by a model in which there is an equilibrium 
between free SNAREs and partially zippered trans-SNARE complexes before exocytosis 
[39, 80].  To date, it has been impossible to characterize the trans-SNARE complexes 
better than this in vitro because of the trans-SNARE complex’s inherent instability and 
propensity to zipper into a four helix bundle. This charicterization was overarching goal 
of my graduate research. 
Several assays have been developed to examine SNAREpin formation in vitro.  In 
one assay, diagrammed in Figure 10, SNARE proteins are incorporated into liposomes 
containing either both of the fluorophores NBD and rhodamine (the v-SNARE 
liposomes) or neither fluorophore (the t-SNARE liposomes). The presence of rhodamine 
in the v-SNARE vesicles quenches the fluorescence of NBD (7-nitro-2-1,3-
benzoxadiazol-4-yl) via FRET, but when fusion occurs, so does lipid exchange, meaning 
the dye-labeled lipids move further apart and the energy transfer between the two 
fluorophores decreases, causing an increase in NBD signal. Thus, fusion can be measured 
as an increase in fluorescence. This method has been used in many papers [45, 82-86] but 
suffers from the limitations that (1) it’s been strictly an in vitro assay, (2) it’s involving 
the fusion of two vesicles, not a vesicle and a flat membrane, and (3) the observed 
kinetics are signifcantly slower than that what occurs in live cells [87, 88]. 
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Figure	  10:	  A	  schematic	  of	  the	  Liposome	  Fusion	  Assay.	  	  A	  liposome	  containing	  both	  v-­‐SNARE	  (blue	  cylinders)	  and	  the	  fluorophores	  NBD	  (green	  stars)	  and	  Rhodamine	  (red	  stars)	  is	  allowed	  to	  interact	  with	  a	  liposome	  containing	  t-­‐SNAREs	  (yellow	  and	  green	  cylinders)	  and	  no	  fluorophore.	  	  Before	  fusion	  NBD	  fluorescence	  is	  quenched	  by	  the	  rhodamine’s	  proximity.	  	  Once	  fusion	  occurs,	  though,	  the	  liposome	  increases	  in	  size,	  allowing	  the	  NBD	  and	  rhodamine	  to	  separate	  in	  space,	  which	  in	  turn	  allows	  NBD	  to	  fluoresce,	  as	  it	  is	  no	  longer	  quenched	  by	  rhodamine.	  	  Fusion	  is	  thus	  measured	  as	  an	  increase	  in	  NBD	  signal.	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In a more biologically relevant assay, the formation of a SNARE complex can 
facilitate fusion between cells when expressed with complementary SNARE motifs 
exposed outside the cells, depicted in Figure 11.  That is, if the v-SNARE is expressed on 
the cell surface of HeLa cells expressing a red cytosolic marker, and if the t-SNAREs 
Syntaxin1 and SNAP25 are coexpressed on the cell surface of HeLa cells expressing a 
blue nuclear marker, after an overnight incubation, fusion can be observed by looking for 
red cells with blue nuclei.  This powerful assay is called a cell-cell fusion assay or a 
flipped-SNARE assay, and it is useful to determine the fusogenic capability of individual 
SNAREs, both wild type and mutant, in a more in vivo manner.  This assay too has been 
used in several assays[89-92] and despite its extreme power, it suffers from a fuew 
limitations too. For example, the membranes which fuse here are not the same 
dimensions as what occurs in vivo.  Also, the time resolution on this assay is one day, so 
kinetics are impossible to discern.	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Figure	  11:	  A	  schematic	  of	  the	  Cell-­‐Cell	  Fusion	  Assay.	  	  A	  subpopulation	  of	  HeLa	  cells	  containing	  t-­‐SNARE	  on	  its	  surface	  is	  created	  so	  that	  it	  has	  a	  blue	  marker	  targeted	  to	  its	  nucleus.	  	  Another	  subpopulation	  of	  HeLa	  cells	  containing	  v-­‐SNARE	  on	  its	  surface	  has	  a	  red	  marker	  targeted	  to	  its	  cytoplasm.	  	  These	  two	  subpopulations	  are	  allowed	  to	  interact	  and	  fuse	  over	  night	  at	  37°.	  	  The	  next	  day,	  fusion	  is	  measured	  by	  examining	  how	  many	  cells	  have	  both	  red	  cytoplasms	  and	  blue	  nuclei.	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ENERGETICS OF SNARE FUSION 	  
Since cognate v- and t-SNAREs fuse membranes without an additional input of 
energy or other proteins as demonstrated by both the cell-cell and liposome fusion assays 
[82, 92],  it is assumed SNARE zippering provides enough energy to overcome the 
repulsive forces that keep membranes apart.  The energy results from the formation of  an 
extremely tight-binding four-helix bundle.  In fact, fully assembled SNARE complexes 
are so stable, they can even resist both SDS and thermal denaturation up to 90°C [37].  It 
is worthwhile to examine the rare stability of this protein complex 
Indeed, as the SNARE complex assembly zippers up from the N-terminal side 
and progresses toward the C-terminal end, 35±7 kBT (around 20 kcal/mol) of energy is 
provided as calculated from Surface Force Apparatus (SFA) experiments, [18] and this 
may be enough energy to overcome the energy barrier due to membrane opposition 
resulting from the immense dehydration forces which has been calculated to be around 
40-50 kBT [18, 93].  At the minimum, SFA measurements establish SNARE fusion 
provides enough energy to hemifuse opposing membranes [19].  The transition of several 
membrane-bound, pre-fusion trans-SNARE complexes to cis-SNARE complexes is thus 
likely to enable fusion of the two membranes. The activation energy for lipid bilayer 
fusion has been calculated to be in the range of 50-100 kBT, so it is likely that more than 
one SNARE complex is required to provide enough energy to drive fusion.  And while it 
is possible that the driving force for membrane fusion might arise from other sources, for 
example, from the energy of protein-lipid interactions or from other, non-SNARE 
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protein-protein interactions, it is extremely unlikely. This suggests that membrane fusion 
occurs spontaneously upon zippering of the SNAREs.  While this may be desirable for 
many biological instances, it is certainly not desirable in all biological circumstances. 
Because trans-SNARE complexes are so unstable and have a high propensity 
toward zippering, at a synapse there must be a layer of control over the spontaneity of 
fusion to ensure synchronous and specific release of vesicle contents upon the arrival of 
the action potential.  Without it, nerve cells would constitutively fire at low levels, 
causing a lack of specificity with regard to nerve cell function. In order to provide that 
layer of control, neurons contain two proteins which help regulate this process, 
Complexin and Synaptotagmin.  These proteins can either raise or lower the energy 
required for fusion, and either inhibit or facilitate the fusion. Complexin and 
Synaptotagmin are thought to be involved in the late stages of SNARE-mediated 
fusion[94], when the t-SNARE is mostly zippered but only the N-terminus of the v-
SNARE is in the four helix bundle. Because this thesis mostly focuses on Complexin, 
Synaptotagmin will only be discussed briefly, and the reader is referred to a number of 
excellent reviews on the subject[64, 85, 95-97]. 
COMPLEXIN 	  
In order to prevent asynchronous release in synaptic fusion, nature has devised 
a clamp/release system which can prevent fusion until the appropriate signal given, while 
still allowing vesicles to build up at the synaptic terminal, and securing a large burst of 
neurontransmitter once an action potential does arrive. This clamp protein is likely a 
member of the Complexin (CPX) family.  Complexins were first identified in 1995 by 
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Ishizuka et al. and McMahon et al., nearly simultaneously.  Ishizuka et al. described CPX 
as a 19kDa protein which copurifies with the SNARE complex, irrespective of the 
detergent used for the solubilization of the complex, suggesting Complexin binds so 
tightly that it does not dissociate from the complex.  In fact, even in the presence of 0.5 
M NaCl, CPX remains associated with the SNARE complex.  They identified Complexin 
as a 134 amino acid protein with a prediction of significant alpha helicity throughout[98].  
McMahon, et al., on the other hand, isolated Complexin based on a search for proteins 
which regulate the SNARE complex, as a family capable of competing with αSNAP for 
binding to the SNARE[99].  Both laboratories discovered that Complexin is a soluble, 
highly charged protein[99, 100]. 
Since its initial discovery, the Complexin family has been found to have four 
isoforms in mammals[101].  CPX1 and CPX2 are widely found in to be expressed in the 
central nervous system[102], but CPX2 is also found relatively ubiquitously, and 
functions in other secretory cell systems [2, 103]. CPX3 appears at very low levels in the 
brain but primarily in the retinal rod cells[101], while CPX4 appears solely in the retinal 
rod and cone cells[101]. CPX1 and 2 share ~80% amino acid identity[104] while CPX3 
and 4 share ~60% amino acid identity to each other, but not to CPX1 and 2 (to which 
they only share about 25% identity) [2, 105].  CPX3 and 4 also possess CAAX boxes at 
their C-termini which tether them to the membranes via prenylation.[101]  Some say 
CPX2 is in excitatory neurons, whereas CPX1 is in inhibitory neurons[104, 106-110], but 
that’s since been discounted.[102]  Also, the kinetics of fusion of CPX3 and CPX4 make 
them suited for the retina.[111]  This protein familiy is highly conserved throughout 
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species with CPX being more than 39% amino acid from C elegans to mice. Disruptions 
in CPX function have been associated with many disorders including, but not limited to 
Schizophrenia[112] , Huntington’s disease[113-117], depression[118-121], bipolar 
disorder[119, 122, 123], Parkinson’s disease[124, 125], Alzheimer’s disease[126],ataxia 
[127, 128], traumatic brain injury[129], social behavior defects[121, 130], cognitive 
function defects [131],Wernicke’s encephalopathy[132], and fetal alcohol syndrome[133, 
134]. Of these, the link between CPX2 and schizophrenia has been the subject of great 
interest of late, as disruption of CPX2 has been shown to be a marker for 
Schizophrenia[106, 107, 112, 119, 120, 122, 135-140].  On the other hand Fung et al. 
recently have suggested that CPX1 or CPX2 expression does not correlate with 
Schizophrenia at all [141]. 
HOW DOES COMPLEXIN REGULATE SYNAPTIC VESICLE FUSION? 	  
Initial biochemical studies showed that both Complexin-1 and Complexin-2 
interact with assembled SNARE complexes through a central α-helical domain, located at 
residues 48 to 70 in mammals, termed, appropriately, the Central Helix 
[142].  Complexin does not bind individual SNARE components[99] or influence 
NSF/αSNAP-mediated disassembly of SNARE complexes[143].  It can, however, weakly 
bind a t-SNARE complex[144]. The binding of CPX to SNARE complexes depends on 
the Syntaxin isoform present[145], and CPX1binds most tightly to, the neuronal syntaxin 
isoform, Syntaxin-1[143, 146].  CPX binds to soluble, assembled, neuronal SNAREpins 
in a 1:1 stoichiometry with kon and koff rates of 3.1•107 M-1s-1 and 0.31/s 
respectively[147].  That is, Complexin binds SNARE complexes rapidly and with high 
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affinity, given its kD value, 10 nM[147].  How does the function of CPX result from this 
tight binding, which is restricted to the fully formed SNARE complex?  
The X-ray crystal structure of the neuronal SNARE-complexin complex, solved 
in 2002[142, 148], helps to answer this question.  It is depicted in Figure 12 and shows 
that a single CPX molecule binds in an antiparallel fashion, directly in the groove formed 
between the VAMP2 and the Syntaxin-1 helices in the four helix bundle.  This binding 
occurs via Complexin’s Central Helix, in agreement with the in vivo requirements for the 
Central Helix to function properly [145, 149-152].  Also shown in the crystal structure is 
a more N-terminal, Accessory Helix, residues 27-47, demonstrated to be responsible for 
Complexin’s actual clamping activity [151, 152].  In the crystal structure, this Accessory 
Helix is running alongside the four-helix bundle without making any physical 
interactions with the SNAREs themselves.  From this structure, it is difficult to predict a 
mechanism of clamping via the Accessory Helix. 
Sadly, the currently available structural data on the Complexin-SNARE 
complex do not provide information on Complexin’s protein domains outside of its 
Central and Accessory Helices, the aptly named N-terminal and C-terminal domains as 
they are likely to be unstructured[143].  However based on deletion and mutation studies, 
the N-terminal domain is thought to be faciliatory to fusion by somehow interacting with 
the C-terminal domains of the SNAREs[151, 153], or potentially interacting with lipid 
membranes [151, 154] perhaps by helping them to form α helices, so a structure of this 
domain would be especially interesting.  To this end, Met5 and Lys6 appear to be the 
most important residues in this region [153].  Interestingly, in C. elegans, the N-terminal 
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domain does not seem to have any effect whatsoever on fusion [152].   
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Figure	  12:	  The	  crystal	  structure	  of	  the	  SNARE	  four	  helix	  bundle	  with	  Complexin’s	  Central	  and	  Accessory	  Helices	  from	  [142].	  	  The	  four	  helix	  bundle	  is	  the	  same	  as	  that	  without	  Complexin;	  namely,	  it	  is	  parallel	  and	  fully	  zippered.	  	  Again,	  the	  t-­‐SNAREs	  are	  yellow	  (Syntaxin1)	  and	  green	  (SNAP25).	  	  The	  VAMP2	  is	  blue.	  	  The	  Complexin	  molecule	  is	  represented	  in	  magenta.	  	  It	  runs	  alongside	  the	  four	  helix	  bundle	  in	  the	  groove	  between	  VAMP2	  and	  Syntaxin	  in	  an	  antiparallel	  fashion.	  	  The	  Central	  Helix	  (dark	  magenta)	  is	  responsible	  for	  interacting	  with	  the	  four	  helix	  bundle,	  and	  the	  Accessory	  Helix	  (light	  magenta)	  is	  responsible	  for	  the	  clamping,	  but	  the	  mechanism	  of	  clamping	  is	  not	  clear	  from	  this	  structure.	  	  The	  N-­‐	  and	  C-­‐terminal	  domains	  of	  Complexin	  are	  not	  present	  in	  this	  X-­‐ray	  structure.	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Further, structural knowledge of the C-terminal domain would be of use given 
its somewhat mysterious role in the fusion process.  Both Xue et al. and Martin et al. 
suggest this domain is inhibitory [150, 152], while Malsam et al. demonstrate this domain 
is facilitatory to fusion [83], perhaps through a predicted amphipathic helix which likely 
targets the C-terminal domain to the membrane [84], and may help deform the 
membrane, priming it for fusion.  In fact, S115 in the C-terminal domain has been shown 
to have a putative phosphorylation site [83, 151, 153, 155], and this prevents binding to 
the membrane, suggesting a potential regulatory role for the C-terminal domain of 
Complexin. Mutation of this serine to an alanine, aspartate, or glutamate resulted in a 
decrease in facilitatory function of the C-terminal domain [83], while mutation of a 
nearby residue to a tryptophan (L117W) increased the Complexin’s facilitatory function 
[84], likely by anchoring the amphipathic helix into the membrane.  This further confirms 
membrane binding is somehow relevant for the facilitatory function of CPX’s C-terminal 
domain.  Because of these distinct functions for individual domains of CPX [151, 152], 
much debate has occurred about the true nature of Complexin’s function.  
IS COMPLEXIN A CLAMP? 	  
In synaptic vesicles, after the vesicles have docked, the trans-SNARE structure 
forms and keeps vesicles at the target membrane, ready to fuse [39].  Under the majority 
of circumstances, SNAREs proceed through the trans-SNARE state very quickly, and 
fusion occurs on the order of less than 1 ms [2]. But at the synapse, a clamp protein is 
required to prevent this rapid fusion; nerve cells require strict temporal control over 
neurotransmitter release for obvious reasons.  As a result of various in vitro and in vivo 
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experiments, it has been postulated that Complexin may, in fact, be this clamp.  However, 
there is significant controversy regarding this hypothesis because depending on cell type, 
organism, experimental approach, or domains of Complexin used, directly opposite 
results are obtained.  In the next few paragraphs, I intend to describe the arguments for 
and against Complexin as a clamp.   
In the earliest studies of Complexin function, injection of antibodies against 
mouse CPX2 into the sea slug Aplysia ganglia was found to increase transmitter release, 
while injection of rat CPX2 decreased it [156], suggesting an Complexin has an 
inhibitory effect on fusion. Further, overexpression of Complexin 1 or 2 in various cell 
lines decreased exocytosis [157].  In PC12 cells, release of acetylcholine and dopamine, 
was decreased [158, 159]; in insulin-secreting β cells, insulin exocytosis was decreased 
[160]; in X. laevis oocytes and renal cell lines [161],  exocytosis-mediated surface 
expression of epithelial sodium channels was decreased, and in chromaffin cells [162], 
release was slowed.  Furthermore, overexpression of a CPX1-VAMP2 fusion protein in 
wild-type GABAergic cortical rat or mouse neurons decreased spontaneous fusion events 
as well as evoked calcium-triggered release [157]. Into Drosophila melanogaster KO 
mutants, when all four mammalian Complexins were individually added back, all 
functioned as fusion clamps [163].  On the other hand, overexpression of Complexin had 
no effect on release in mouse hippocampal neurons (CPX1) [151] or glutamatergic 
hippocampal neurons (CPX3 & 4)[164]. In porcine oocytes, CPX is responsible for the 
docking process of cortical granules [165].  Furthermore, in vitro studies of Complexin 
have demonstrated it does, in fact, act as a clamp in both the cell-cell fusion [91] and 
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liposome fusion assays [166]. Based on these lines of evidence, having extra Complexin 
in a cell is conducive to clamping fusion. 
On the other hand, antibody attempts to perturb CPX function as well as 
Complexin knockouts often lead to the conclusion that CPX has a faciliatory role in 
fusion.  For example, injection of a Complexin “blocking peptide,” meant to disrupt 
Complexin’s interaction with Syntaxin in squid giant presynaptic terminals reduced 
neurotransmitter release [167].  The introduction of anti CPX1/2 antibodies into 
permeabilized human sperm cells decreased acrosome exocytosis [168]. Antisense 
knockdown of Complexin in renal cells decreases exocytosis[169], as does RNAi 
knockdown of CPX1 in insulin-secreting β cell lines [160], and antisense DNA-mediated 
knockdown of CPX2 in mast cells [169].   Knockouts of CPX in mouse hippocampal 
neurons [102], sperm [170],  D. melanogaster neuromuscular junctions [171], and 
vertebrate autapses [102, 151] have all decreased exocytosis.  Thus, the removal of 
Complexin appears to decrease fusion as well, suggesting a facilitatory role for the 
protein in membrane fusion. On the other hand knockout of D. melanogaster CPX 
actually stimulates calcium-independent fusion in neuromuscular junctions [171], 
suggesting an inhibitory role. And KO of CPX1 in mouse auditory synapses impaired 
synchronization of release [172].  Furthermore, deleting Complexin in C elegans 
decreases calcium-evoked release, but increases non-calcium-specific “tonic” release 
[152, 173].   Other in vitro experiments suggest Complexin stimulates fusion [83, 144].  
Clearly the understanding of Complexin’s function in vivo is lacking. 
Because of this debate, many labs have settled on the conclusion that 
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Complexin has a dual function [144, 151, 152, 154, 163, 173-175].  And while this is an 
attractive model, the mechanism remains unexplained.  Perhaps, as Xue et al. suggest, 
various domains of CPX in various species interact differently and are inhibitory or 
facilitatory to various extents [150].  Another option is that the protein operates 
differently at different times; it may facilitate fusion by interacting with the SNAREs to 
help their N-terminal regions to come together but then arrest fusion by blocking the 
association of the v-SNARE’s C-terminal domain with the remainder of the four helix 
bundle.  The differences among species may be due to slight variations in the sequences 
of the N-terminal domain, the Accessory Helix, or the C-terminal domain.  Surely the 
interplay among all four domains of Complexin warrants further study. 
Assuming CPX is a clamp, or at the very least that its Accessory Helix does 
clamp SNARE fusion, an unanswered question in the field has been just how it clamps 
the SNARE assembly in the trans- state, and with which domains of the synaptic proteins 
it interacts at this state.  In the Complexin-SNARE complex crystal structure [142], the 
Accessory Helix is localized near the SNARE domains’ C-termini which link the SNARE 
motifs of VAMP2 and Syntaxin with their respective transmembrane domains.  Thus, one 
possibility proposed by both Tang et al. and Brose [2, 157] is that the Accessory Helix 
simply has a sterical effect; that is, it might interfere with the full zippering of the 
SNARE complex, and thereby prevent full fusion.  A similar proposal is that the 
Accessory Helix blocks the zippering not only by sterics, but by actually binding to the 
pre-structured C-terminal SNARE domains of the t-SNAREs [89, 175].  In this model, 
first proposed by Giraudo et al. in 2009 [89] and depicted in Figure 13, the Accessory 
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Helix prevents VAMP2 from forming the four helix bundle by forming an intramolecular 
“alternate four-helix bundle,” and specific residues in the CPX Accessory Helix help 
form the hydrophobic layers while other hydrophilic residues prevent the extra-tight 
binding VAMP2 natively possesses and allow the clamp to be released [89, 175].  This 
model was further supported by mutagenesis in the Accessory Helix region in which 
changes were made to make the Accessory Helix have even more hydrophobic layer 
contacts, and they caused CPX to be a better clamp, as evidenced in the cell-cell fusion 
assay [89].  On the other hand, when the corresponding hydrophilic mutations were 
made, no clamping function was observed whatsoever [175].	  	  
Another recently proposed model [175] suggests that Complexin clamps fusion 
by blocking a secondary calcium sensor, working in tandem with Synaptotagmin to 
clamp release.  While I cannot rule out this mechanism, the identity of this secondary 
calcium sensor remains a mystery.  A suggest of an as-yet-unidentified protein is 
proposed [176].  In light of what will be presented in the following chapters, however, I 
find this model unlikely. 	  
 	   	   	   	  
40 
	  
Figure	  13:	  The	  Intramolecular	  Alternate	  Four	  Helix	  Bundle	  Model.	  	  This	  structure	  was	  proposed	  in	  [89]	  as	  a	  model	  for	  the	  clamped,	  trans-­‐SNARE	  structure.	  	  The	  t-­‐SNAREs	  are	  represented	  in	  yellow	  and	  green	  (Syntaxin	  and	  SNAP25,	  respectively),	  as	  previously,	  and	  VAMP2	  is	  represented	  in	  blue	  again	  as	  well.	  	  VAMP2	  is	  truncated	  to	  represent	  the	  lack	  of	  zippering	  of	  its	  C-­‐terminus	  Complexin	  is	  magenta,	  and	  its	  Central	  Helix	  binds	  as	  before	  [142],	  but	  its	  Accessory	  Helix	  comes	  in	  and	  binds	  in	  the	  region	  where	  the	  VAMP2	  would	  have	  bound	  were	  it	  zippered,	  which	  would	  block	  the	  full	  zippering	  of	  VAMP2,	  according	  to	  this	  model.	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Even in light of the observation that distinct domains of Complexin can 
regulate neurotransmitter release differently [151], the fact that Complexin affects 
SNARE-mediated vesicle fusion in a predominantly facilitatory manner in certain 
settings and an inhibitory manner in others remains confusing.  It is possible that the in 
vitro fusion assays do not recapitulate all aspects of Complexin in vivo due to the lack of 
certain binding partners as yet unidentified.  The inhibitory effect of the Complexin 
Accessory Helix might also be exaggerated in the in vitro assays, causing a net reduction 
in fusion activity.  It is also possible, as Xue et al. suggest [151], that certain organisms’ 
Complexins are more designed for clamping, while others are designed for a faciliatory 
role helping to explain the difference between organisms.  On the other hand, it is 
possible that in vivo, there is another undiscovered protein, or an unknown function of a 
known protein that can act on this system which can confound in vivo results.  An answer 
to the question of how CPX can be both an activator and an inhibitor of fusion has been 
suggested by Li. et al., 2011 (under submission). In this paper, the authors suggest that 
while the Accessory Helix is responsible for the clamping activity observed in CPX, the 
Central Helix (and potentially both the N-terminal and C-terminal domains) serve to aid 
the CPX in helping the trans-SNARE complex to form.  Thus up to three domains help 
the SNARE domain to form into a meta-stable trans-SNARE, while the other domain 
prevents the full fusion of the SNAREs until acted upon by an external signal. To be 
specific, in the absence of Complexin, v- and t-SNAREs assemble and yield ~35 kBT per 
SNAREpin at a distance of 9nm.  In the presence of CPX, the SNAREs begin to assemble 
at a greater distance (15 nm) and form a SNAREpin of lower energy (~15 kBT) which has 
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its membrane-proximal zippering inhibited.  This is the first time the energetics of a 
fusion intermediate structure have been described.  While this is an appealing model, for 
now, some aspects of CPX’s activity must remain a mystery. 
HOW IS THE COMPLEXIN CLAMP RELEASED? 	  
It is known that fusion is induced by an increase in the local calcium 
concentrations in the presynaptic bulb.  Katz et al. established that synaptic vesicle 
exocytosis is triggered by calcium in 1969 [8].   So, identification of the calcium sensor 
that regulates the fusion reaction would help with understanding this pathway. A protein 
called Synaptotagmin (SYT) is likely just this protein. Identified first in 1981 by Matthew 
et al. as a 65 kDa protein exposed on the outer surface of neuronal synaptic vesicles 
alongside VAMP2 [177], it wasn’t until a decade later that this protein was named 
“Synaptotagmin” [178]. It was discovered that Synaptotagmin can bind both calcium and 
acidic phospholipids like phosphotidylserine [179, 180]. It has since been shown that 
Synaptotagmins form a large family of proteins with seven members in Drosophila and 
17 members in mammals [181].  Since SYT1 is the most abundant calcium binding 
protein present on synaptic vesicles, accounting for seven percent of the total vesicle 
protein, it was an obvious target of investigation for the calcium sensor [182, 183].   
Synaptotagmin is thought to be the protein responsible for release of the CPX 
clamp not only because it has calcium binding sites, but also various lines of in vivo 
evidence [157].  For example, in flies, Synaptotagmin functions to synchronize 
exocytosis during calcium-evoked stimulation[179]. Synaptotagmin KO synapses exhibit 
a ~10 fold increase in spontaneous release. In addition, knockout mice have greatly 
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reduced synchronous transmitter release following nerve stimulation [184].  Xue et al 
found evidence for a genetic interaction between Complexin and Synaptotagmin [153]. It 
has even been suggested that Synaptotagmin and Complexin compete for a binding 
site[157]. On the other hand, Yang et al. suggest that Syaptotagmin acts at a stage later 
than that of Complexin [175].  Because a lack of Synaptotagmin is tied to a lack of 
synchronicity in fusion, SYT is likely responsible for tying fusion to calcium influx.  On 
the other hand, in nerve cell cultures from Synaptotagmin knockouts, fusion still occurs 
as normal [182, 185], suggesting a deletion of Synaptotagmin has no effect on fusion in 
these cells. And in still other studies in Synaptotagmin-deficient mutants reported 
increases in the rate of spontaneous vesicle fusion events [186-188], suggesting 
Synaptotagmin may not be responsible for releasing the Complexin clamp.  In vitro, 
however, in the same cell-cell fusion and liposome fusion assays that demonstrated CPX 
is a clamp, Synaptotagmin is able to release the clamp imposed by Complexin upon 
influx of calcium in keeping with the model in which Synaptotagmin senses calcium and 
causes the release of Complexin.  Clearly more research is warranted into the true roles of 
and interplay between Synaptotagmin and Complexin, an interplay which is present in 
organisms as primitive as Trichoplax [175] which has both CPX and SYT analogs but no 
known nervous system.  This suggests this interplay is of such importance, evolution 
sought to maintain it through millions of years. Because Synaptotagmin is thought to bind 
an inherently unstable partially-zippered trans-SNARE structure, structural information 
on these interactions is extremely difficult to obtain.  
What is known structurally is that Synaptotagmin has a short intraluminal 
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domain, a single membrane-spanning domain, and a large cytoplasmic domain consisting 
of two C2, calcium-binding domains, called C2A and C2B, connected by a linker [178, 
184, 189, 190], which is presented in figure 14.  The crystal and NMR structures of 
Synaptotagmin showed the C2 domains exist as compact eight stranded beta barrels, each 
with two protruding loops which can bind three calcium ions or phospholipids through 
five conserved aspartate residues from the top loop [191-194]. Other findings suggested 
that SYT’s ability to bind calcium and phospholipids involves electrostatic interactions 
between basic lysine patches on the C2A domains and the charges on phospholipid 
headgroups, insertion of hydrophobic residues into the lipid bilayer, and coordination of 
the calcium ions by these headgroups [195]. 




Figure	  14:	  The	  Synaptotagmin	  Crystal	  Structure.	  	  This	  is	  the	  crystal	  structure	  of	  Synaptotagmin,	  showing	  the	  two	  calcium-­‐binding	  domains,	  C2A	  and	  C2B.	  	  The	  calcium	  they	  bind	  is	  shown	  in	  red,	  and	  the	  basic	  residues	  on	  the	  surface	  are	  shown	  in	  blue	  and	  purple.	  	  The	  positioning	  of	  the	  C2A	  and	  C2B	  with	  respect	  to	  each	  other	  is	  not	  fully	  known,	  and	  their	  relative	  orientations	  with	  respect	  to	  the	  SNAREs	  is	  also	  unknown.	  From	  (Chapman	  2008)	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Interestingly, mutations in the calcium binding sites that severely impair 
calcium and phospholipid binding to the C2A domains have only small effects on vesicle 
fusion [189, 196, 197].  This was explained by examining the other C2 domain in 
synaptotagmin, the C2B domain. Structurally, the C2B domain resembles the C2A 
domain, as it also contains conserved aspartate residues [185].  Further, C2B also binds 
the membranes via lipids like PIP2 and PS, suggesting that the two C2 domains may 
cooperate with each other in both calcium and phospholipid membrane binding [194, 
198].  In fact, when the aspartates of the Ca2+-binding loops of either the C2A and C2B 
domains (or both) were replaced by tryptophan residues (thereby increasing the 
hydrophobic surface area, effectively inserting them into membranes more efficiently), 
there are increases in the apparent calcium affinity of the Synaptotagmin and the calcium 
sensitivity of vesicle fusion [196, 199].  This suggests there is a link between the 
calcium-binding and thus membrane-binding ability of Synaptotagmin in vitro and the 
calcium sensitivity of neurotransmitter release in vivo. Further, this provides evidence 
that membrane binding is required for Synaptotagmin’s calcium-dependent release of the 
Complexin clamp. 
Both the C2A and the C2B domains bind phospholipids in a Ca2+-dependent 
manner, and it has been shown that calcium induces simultaneous binding of 
Synaptotagmin to both the vesicle and target membranes, bringing the two membranes 
into close proximity (about 4 nm) [200]. The C2B domain appears to be the most 
responsible for this property, owing to the abundance of basic lysine residues which 
interact with the negatively charged phospholipids around its surface [193]. 
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Taken all together, this leads to a model wherein, Complexin somehow 
prevents full zippering of the SNARE complex via its Accessory Helix.  As a result of an 
action potential, calcium enters, and Synaptotagmin binds the membranes and cooperates 
with Complexin and the SNAREs in releasing the CPX clamp and bringing the synaptic 
vesicle and plasma membranes together allowing fusion to occur.  In one model, the C2A 
domain of Synaptotagmin would have an accessory role, helping to bind phospholipids 
and contributing to the overall Ca2+ sensitivity of release while the C2B domain takes the 
dominant role in membrane binding and thus calcium-dependence on fusion 
[85].  Another possible mechanism is that both C2A and C2B bind membranes, and upon 
the calcium stimulus, a large rearrangement of Synaptotagmin occurs, severely disrupting 
the membranes and disrupting the CPX clamp somehow [201].  The goal of this thesis is 
to understand both how Complexin clamps, and also to gain some idea of how this clamp 
is released. 
A NOVEL MODEL FOR CLAMPING AND RELEASE 	  
In order to address the question of how the Accessory Helix of Complexin 
actually clamps SNARE-mediated fusion, and to assay the nature of the trans-SNARE 
complex, our collaborators solved a crystal structure of the four helix bundle, lacking the 
C-terminus of VAMP2, but in the presence of the Accessory and Central Helices of 
Complexin.  This structure might serve as a mimetic of the trans-SNARE, wherein the C-
terminus of the v-SNARE is not zippered.  Interestingly, the solved structure is somewhat 
unexpected, and required external validation.  My first goal was to develop a FRET assay 
that would validate their crystal structure (Chapter 2).  From there, I extended the FRET 
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assay to further examine the nature of the trans-SNARE complex.  From these 
experiments, we were able to develop a novel intermolecular clamping model which may 
even help explain how CPX can both stabilize the formation of the trans-SNARE 
complex, priming vesicle fusion, while also preventing fusion from occurring (Chapter 
3).  After that, I used the same FRET-based assay to examine the mechanism by which 
the CPX clamp is released.  I identified three residues on VAMP2 which are required to 
permit CPX to unclamp (Chapter 4).  In Chapter 5, I elaborate on the proposed model, 
discuss some of its limitations, and make some testable predictions that can further 
extend this work both in vivo and in vitro. 
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FRET INTRODUCTION 	  
 My thesis project began as a validation of a crystal structure, which, in essence, 
means my aim is to determine interatomic distances.  While either NMR or EPR might be 
able to determine distances, a much faster, and relatively accurate method of distance 
determination is FRET (Förster Resonance Energy Transfer).  FRET is a method by 
which one fluorophore is excited and instead of emitting at its normal wavelength, its 
emission energy is transferred to a second fluorophore, in a distance-dependent manner.  
Based on the energy transfer, one can determine the proximity of two fluorphores.  In 
addition to its speed, FRET is useful because it can be performed at low protein 
concentrations (1-2µM), which eases experimentation.  It is worthwhile to discuss how 
FRET occurs, if only briefly, to help understand the principle thrust of my contributions 
to the following chapters. 
THE PHYSICS OF FRET 	  
 The physics of fluorescence is well-established and reviewed in [1, 2], and is 
briefly presented here. The internal energy of a molecule in a stable state is, to a first 
approximation, a function of its electronic energy.  However, there are two more 
contributions to a molecule’s internal energy: vibrational and rotational energy.  Possible 
energy states of a molecule in terms of electronic energy, vibrational energy, and 
rotational energy can be diagrammed (Figure 15).  The differences between levels of 
electronic energy are larger than the differences between levels of vibrational energy, and 
those in turn are larger than the differences between levels of rotational energy; in fact, 
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rotational energy can be, and is often neglected in the diagrams and in everyday 
calculations.  Absorption of a photon by a molecule imparts energy, hν, to the electron 
distribution and thus an oscillation at a frequency ν, to an electronic dipole of the 
molecule.  This transition dipole will be shown to be a important soon. 
 First, one must consider the change in energy state of a molecule that has 
interacted with a photon.  The Jablonski diagram in Figure 16 describes the increase in 
electronic energy after absorbing a photon and the relaxation from higher, excited energy 
states back to the ground state.  The energy of the absorbed photon raises both electronic 
and vibrational energy to new levels, depending on the wavelength of the photon and its 
absorption probability.  The excited-state molecule then loses energy to its surroundings, 
and the electronic energy relaxes back to the lowest vibrational state of the lowest energy 
excited state, the ground state (S0 in Figure 16).  This excited-state lifetime is referred to 
as the fluorescence lifetime, τ.  It is defined as 
          (1) 
where kf is the rate of relaxation from the lowest energy excited state to the ground state 
by emitting a photon (called fluorescence) and knr is the rate of relaxation to the ground 
state by all other processes, not involving emission of a photon (nr is for nonradiative). 
 The fluorescence lifetime can be derived from the decay of fluorescence intensity 
in a population of molecules excited simultaneously, a measureable parameter.  The 
intensity of the population (I) decays exponentially as a function of time t and lifetime τ.   
           (2)  
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Figure	  15:	  A simplified version of the energy levels a molecule can sample from [1].  The largest steps in 
energy differences are in electronic energies.  These are bridged by both vibrationally (medium sized steps) 
and rotationally (smaller sized steps) determined energy states. 	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Figure	  16:	  A sample Jablonski diagram.  This Jablonski diagram from [1] depicts the absorption of energy 
by a molecule to a higher energy state, S2, and successive relaxation events that can occur for that molecule 
so it can reach ground state, S0, again.  Fluorescence is one such process of energy release, in which a 
photon is released, bringing a molecule from a higher energy level to its ground state.  FRET occurs when 
the energy absorption by one molecule is released by nonradiative transfer of the energy to a second 
molecule, exciting it instead, and bringing the initial molecule back to ground level without release of a 
photon. 	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 One of the mechanisms for energy loss contained in knr is radiationless transfer of 
energy from the excited state dipole of one fluorescent molecule, the donor, to a 
transition dipole of another fluorescent molecule, the acceptor.  This process is called 
Fluorescence Resonance Energy Transfer (FRET) and is the result of a distance 
dependent, through space, dipole-dipole interaction which occurs between an excited 
donor and an unexcited acceptor, and reviewed in [2, 3].  FRET theory predicts that 
energy could be transferred by the resonance dipole-dipole mechanism over a distance 
from ten to 100Å, depending on the spectroscopic parameters of the donor and acceptor.  
The rate of energy transfer, kT is described by the following equation: 
           (3) 
where τD is the donor lifetime in the absence of acceptor, R is the donor-acceptor 
distance, and R0 (called the Förster critical distance) is a distance calculated from 
spectroscopic data  and the mutual dipole orientation of the donor and acceptor.  R0 is an 
important intrinsic parameter between two fluorophores because it defines the distance 
between the donor and acceptor fluorophores at which the probability of donor de-
excitation by energy transfer is equal to the sum of probabilities of all other deactivation 
processes that occur in the absence of the acceptor.  That is, 50% of the energy from the 
donor is transferred to the acceptor. The Förster critical distance is defined by equation:  
         (4) 
where κ2 is the orientation factor for dipole-dipole interaction determined by the angle 
between the donor and acceptor dipoles, QD is the fluorescence quantum yield of the 
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donor in the absence of the acceptor, n is the refraction index of the medium between the 
donor and the acceptor, N is Avogadro’s number, and J is the normalized spectral overlap 
integral, given by 
        (5) 
where FD(λ) is the fluorescence intensity of the donor in the absence of the acceptor at 
wavelength λ, and εA(λ) is the molar absorption coefficient of the acceptor at λ. 
 The efficiency of transfer of the energy transfer, ET, is a quantitative measure of 
the number of photons that are transferred from donor to acceptor.  ET is the ratio of the 
rate, kT to the total sum of rate constants of all processes by which an excited donor 
molecule can return to its ground state, including kT. 
        (6) 
where the subscript i refers to the different pathways of deactivation from the excited 
donor state, and τDA is the measured fluorescence lifetime of the excited state of donor in 
the presence of acceptor.   
 The energy transfer can be measured in several different ways: enhanced 
fluorescence of the acceptor, decreased fluorescence of the donor, decrease of the donor 
fluorescence lifetime, change in the anisotropy of the donor and the acceptor, and/or 
donor photobleaching.  In my case, I chose donor fluorescence decrease out of sheer ease. 
 The distance between the donor and the acceptor may be calculated from the 
efficiency of energy transfer and using the following equation: 
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          (7) 
 
The practical importance of R0 is that it provides a handle for estimating the range of 
distances for which FRET can be observed for any given probe pair.  Because of the strict 
distance dependence of energy transfer (it is a function of distance to the sixth power), 
steady state FRET measurements should be carried out within the value of ±50% of R0. 
 In biomolecules, FRET can be utilized either via fluorophores native to the 
biomolecule such as tryptophan or tyrosine in proteins, naturally fluorescent fusion 
proteins like GFP or RFP, which can be engineered into the sequence of the protein, or 
via small organic fluorophores which can be specifically coupled to unique sites in these 
biomolecules, often through maleimide-cysteine chemistry in proteins.  In general 
interchomophoric distance is greater than that of the alpha carbons of the amino acids to 
which they are attached by about 5-10Å.  FRET occurs between delocalized electrons in 
the probes rather than between the side chains of the amino acid residues. Lankiewicz et 
al.[3] reviews the validity of this assumption and shows FRET compares to X-ray 
crystallography and NMR and that there is a general agreement among the three. 
 In addition to finding R0 for a given FRET pair, the orientation factor, κ2 must 
also be determined.  It can vary from 0 to 4, but the actual value of κ2 rarely assumes 
these values.  In general, it is assumed that if the dyes are freely rotating, κ2 is equals 2/3. 
In order to calculate κ2, one must therefore determine whether one’s dyes are freely 
rotating.  A fluorescent molecule excited by plane-polarized light will emit polarized 
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fluorescence.  The degree of polarization depends on the molecule’s motion during the 
lifetime of its excited state. That is, if a molecule is freely rotating, it doesn’t maintain its 
polarization as well as a rigid molecule.  So, a measure of the emitted light’s polarization 
can be used to determine the validity of the freely rotating assumption. The polarization 
of emitted fluorescence is usually read out as anisotropy, r, 
          (8) 
where I||  is the intensity of the population when the emission filter is parallel to that of 
the excitation filter, and   is the intensity when the two filters are perpendicular.  FRET 
occurs, then r total fluorescence intensity IDA (for a single species of fluorophore) or rdonor  
acceptor fluorescence, IA (for different species of donor and acceptor).  Anisotropy can 
therefore be used to determine the ability of the fluorophore to freely rotate, suggesting 
the goodness of 2/3 being chosen for κ2. 
FLUOROPHORE CHOICE 	  
 In cell biology systems, among the most common FRET partners include the 
family of GFP proteins [4-8].  Their value lies in their ability to be expressed as fusion 
proteins with the protein of interest, allowing direct visualization within a cell using 
confocal fluorescence microscopy [9]. In single molecule biophysics, the commonly used 
FRET fluorophores include the Cy dyes and the Alexa dyes [10-14], which are extremely 
bright dyes which can bind via maleimide-cysteine chemistry.  These bright dyes have 
become more useful of late due to their brightness, and ability to be visualized in single-
molecule experiments. 
 	   	   	   	  
81 
 The benefits of both of these classes of fluorophores in many systems are actually 
detriments for my goals, however.  Because they are so bright, they have relatively large 
overlap integrals (J), meaning they have large R0 values, in the 50-60 nm range [11, 15], 
meaning they will be reliable for determination of distances from around 30-100Å.  The 
distances I have to measure, though, are in the 20-40Å range.  Commonly used FRET 
pairs for shorter distance measurements often involve engineered tryptophan residues 
paired with other relatively weak fluorphores. like EDANS (5-[(2-
aminoethyl)amino]naphthalene-1-sulfonic acid), ANS (8-anilonaphthalene-1-sulfonate), 
or pyrene (reviewed in [16] and references contained therein), which have R0 values on 
the order of 20-25Å, which would be perfect for the distance calculations I want to 
measure.  Unfortunately VAMP2 has two native tryptophans in its C-terminus which are 
likely essential for its functioning [17]; in addition, the t-SNAREs also have native 
tryptophans as well, so to do experiments using tryptophan as my donor might affect how 
the SNAREs behave.  Another problem with mutating native tryptophans out of proteins 
is that it renders the protein concentrations difficult to assay via standard UV280 
spectroscopic methods.  So, instead of mutating out the SNAREs’ native tryptophans, I 
removed the few native cysteine residues where were in the proteins and used thiol-
maleimide chemistry to bind fluorophore pairs with small R0 values. 
 Unfortunately, there are not many of these fluorophores in existence [16], and the 
ones that do exist have problems such as low solubility in aqueous buffers and low 
labeling efficiency due to poor reactivity with the thiol group.  In the course of my 
attempts, I tried (EDANS/NBD), (Bimane/NBD), (Pyrene/Bimane), among others.  I 
 	   	   	   	  
82 
found NBD to be extremely insoluble in water, making it nearly impossible to work with 
for my proteins.  Pyrene, on the other hand, forms homo-excimers [18], an interaction 
between the ground state of one pyrene molecule and the excited state of a second pyrene 
molecule.  This would unnecessarily confound my data and would lead to no real benefit.  
 As none of these previously used short distance FRET pairs would work for me, I 
ended up developing a novel FRET pair.  Stilbene has similar fluorescent properties to 
pyrene, so I chose to pair it with pyrene’s partner, bimane [19], and carried out the tests 
to determine whether it would work.  That is, I calculated its quantum yield (QD) to be 
0.19, using tryptophan as the reference [16].  I also performed polarization measurements 
and determined that the anisotropy values were around 0.1, which suggests that the FRET 
probes have isotropic motion.  This allowed me to use 2/3 for my orientation factor, κ2.  I 
also used a refractometer to measure the refractive index of my buffer (η = 1.358).  From 
these values, I calculated R0 to be 27.5Å for the Stilbene/Bimane FRET pair, which is 
well in the range to measure the distances I want to measure.  As a control, and to 
validate my initial experiments, I also used a previously published Bimane/Oregon Green 
FRET pair [20] as validation. 
 FRET data were collected on a Perkin-Elmer LS55 luminescence spectrometer, 
operating at 25°C.  Excitation and emission slits of 5 mm were used in all experiments.  
Both buffer alone and acceptor alone samples were subtracted from the scans to eliminate 
any fluorescence excitation due to the buffer or any excitation of the acceptor molecule at 
the donor molecule’s excitation wavelength.  Efficiency of transfer values were then 
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calculated by examining the decrease in the donor fluorescence as compared to a donor-
only sample and using  
 E =1! fDAfD
         (9) 
where fD is the donor fluorescence intensity measured in the absence of acceptor and fDA 
is the donor fluorescence intensity measured in the presence of acceptor and E is the 
efficiency of transfer.  This value was then corrected for acceptor molecule percentage 
labeling using 
 E =1! fDAfD
         (10) 
where the corrected efficiency was calculated by dividing the observed efficiency by the 
fraction of molecules labeled with acceptor, fA.  Distances were then calculated using 
formula (7) above. 
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 The model put forth in GIRAUDO ET AL, figure x, proposes that the Accessory 
Helix of Complexin clamps fusion by binding to the pre-zippered C-terminus of the t-
SNARE preventing the binding of the VAMP2 C-terminus.  We collaborated with the 
Reinisch lab at Yale University to examine this model crystallographically. The key to 
the solving of the crystal was twofold: first, we truncated the VAMP2 at residue 60 with 
the thought that, if it is not present, the C-terminus cannot zipper.  Second, we used the 
superclaming mutant of Complexin (residues) to assist it in being able to bind better. 
 Once the crystal structure was solved, one major concern was that it was solely an 
artifact of either high concentration and crystal packing or truncation of the v-SNARE.  
In order to ensure that the observed crystal structure is real and not an artifact of 
crystallization, I developed a FRET-based assay to determine the positioning of the 
Accessory Helix in Complexin.  After validating that the crystal structure was, in fact, 
real, we also examined its energetics via Isothermal Titration Calorimetry (ITC) as well 
as its functional consequences using both liposome fusion and cell-cell fusion assays and 
arrived at a model of the clamping process.  
 This paper provides an explanation of how Complexin, and specifically its 
Accessory helix can clamp fusion.  My contribution of the FRET studies helped to prove 
that the crystal structure is valid. 
   






Complexin cross-links pre-fusion SNAREs into a zig-zag array:  
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Complexin prevents SNAREs from releasing neurotransmitters until an action 
potential arrives at the synapse. To understand the mechanism for this inhibition, we 
determined the structure of complexin bound to a mimetic of a pre-fusion SNAREpin that 
lacks the portion of the v-SNARE which zippers last to trigger fusion. The “central helix” 
of complexin is anchored to one SNARE complex while its “accessory helix” extends 
away at ~45º and bridges to a second complex, occupying the vacant v-SNARE binding 
site to inhibit fusion. That the accessory helix competes with the v-SNARE for t-SNARE 
binding was expected, but surprisingly, the interaction occurs inter-molecularly. Thus 
complexin organizes the SNAREs into a zig-zag topology which, when interposed 














Information processing in all nervous systems requires the correlation of events in 
the external world with internal representations, and therefore relies on transmission of 
signals between neurons that are precisely timed and that retain coherence. This, in turn, 
requires that the release of neurotransmitters at synapses also be precisely timed, 
following immediately the arrival of a nervous impulse. The physiological and 
anatomical mechanisms have long been known1,2. Synaptic vesicles containing 
neurotransmitter are already docked at the “active zones” of the pre-synaptic membrane, 
ready to respond to the elevated calcium levels that accompany an action potential by 
releasing neurotransmitter. 
In recent years, much has also been learned about the molecular mechanisms 
underlying this physiology. The central players in neurotransmitter release are the 
SNARE proteins3. These are the engines that drive membrane fusion between cargo-
carrying vesicles and the plasma membrane4,5 as v-SNAREs (anchored in the vesicle 
membrane) zipper into a coiled-coil four helix bundle with cognate t-SNAREs (anchored 
in the plasma membrane)3-6. In synapses, a major v-SNARE is VAMP2, and the t-
SNARE proteins are SNAP25 and syntaxin1, where VAMP2 and syntaxin1 each 
contribute one helix to the coiled-coil and SNAP25 contributes two7. Another vital 
component is synaptotagmin, a synaptic vesicle protein8 that binds calcium ions9 and is 
the immediate sensor and trigger for vesicle fusion10-12. How precisely synaptotagmin 
couples to SNAREs to trigger fusion remains unknown. 
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But whatever the mechanism, rapid and synchronous release of neurotransmitter 
requires that the fusion process by SNARE proteins be frozen in place, or “clamped”3, 
when it is well advanced. This is because fusion by SNARE proteins is spontaneous4,5 
and must therefore be inhibited to prevent continuous release of neurotransmitters. This is 
also because neurotransmitter release takes place on a much shorter time scale than the 
entire process of vesicle docking and fusion complex assembly. For example, fusion of 
artificial vesicles bearing v-SNAREs to planar lipid bilayers containing t-SNAREs 
requires 10-100 msec following docking13-15, whereas neurotransmitter release can take 
place in one millisecond or less after calcium entry. Thus, fusion must be clamped at a 
very late stage in synapses. 
A combination of biochemical, genetic, and physiological results have clearly 
pinpointed complexin (CPX)16,17 as the central component of this clamp18-20. Since CPX 
both facilitates and inhibits synaptic fusion21-26, it has been proposed to act by catalyzing 
the initial stages of SNARE assembly, but then clamping further assembly until the 
arrival of an action potential (reviewed in27). The thermodynamic basis by which CPX 
can function both as an activator and a clamp for SNARE assembly is explored in a sister 
manuscript28. 
Structures of CPX bound to a post-fusion fully assembled SNAREpin29,30 yielded 
first insights regarding the facilitatory mechanism, but did not resolve how CPX inhibits 
fusion. In the post-fusion/SNARE structures, CPX forms a continuous helix parallel to 
the SNAREpin coiled-coil, with a “central helix” portion of CPX (CPXcen, residues 48-70 
in hCPX1) contacting both the v-SNARE and t-SNARE in the membrane-distal portion 
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of the SNAREpin. This is the portion of the SNAREpin that zippers first, and it is thus 
possible that CPX facilitates initial assembly30. The remainder of the CPX helix, termed 
its “accessory helix” (CPXacc, residues 26-47 in hCPX1), parallels the C-terminal 
membrane-proximal portion of the fully zippered SNARE complex, but does not interact 
with it.  
Nonetheless, the accessory helix is needed to create the clamped, pre-fusion 
state21,31 in which the membrane-distal N-terminal portions of the SNARE coiled-coil 
have zippered, but the membrane-proximal VAMP2 C-terminus has not yet associated 
with the corresponding regions of SNAP25 and syntaxin118,21,32-34. Biochemical and 
spectroscopic experiments strongly support a mechanism whereby CPXacc directly 
competes with the VAMP2 C-terminus for binding to the t-SNARE19,35 - but how this 
happens has been unclear in the absence of structural studies with pre-fusion SNARE 
complexes.   
We have therefore designed a half-zippered soluble mimetic of the pre-fusion 
synaptic SNAREpin, and we have solved its structure when bound to complexin. 
Remarkably, we find that the CPX accessory helix extends away from the SNAREpin, 
and binds a second SNAREpin to inhibit its assembly. Solution and functional studies 
confirm both the CPX conformation and the interaction between the accessory helix and 
pre-fusion SNAREpin observed in the structure. Our studies thus suggest that complexin 
cross-links pre-fusion SNARE complexes into a zig-zag array. This array, when 
interposed between the vesicle and plasma membrane, provides a further barrier to 
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fusion. Although cross-linking the CPX/SNARE array may block fusion, it also orients 




RESULTS AND DISCUSSION 	  
STRUCTURES OF A “PRE-FUSION” SNAREPIN AND ITS COMPLEX WITH 
CPX. 
The pre-fusion form of the SNARE complex is a transient intermediate stabilized 
in part by the simultaneous insertion of SNAREpins into two membrane bilayers, and 
hence is not readily accessible for structural studies. Zippering up begins as the pre-
folded N-terminal portions of VAMP2 associate with the pre-assembled t-SNARE 
complex36-38. In designing a soluble pre-fusion SNARE mimetic suitable for structural 
studies, we therefore prevented the completion of zippering by C-terminally truncating 
the VAMP2 SNARE motif. This SNARE complex (SNAREΔ60) also contains residues 
190-253 of rSyntaxin1A and residues 10-82 and 141-203 of hSNAP25A. 
We determined the structure of this truncated SNARE complex at 2.2 Å 
resolution (Table 1). Except for the absent VAMP2 C-terminus, the truncated SNARE 
complex in our studies superimposes well with fully assembled SNARE complexes 
studied previously (rmsd 0.77-0.97 Å)7,30. A notable finding is that the syntaxin1 and 
SNAP25 helices are almost fully formed even in the absence of the VAMP2 C-terminus 
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(Figure 17A), suggesting that the t-SNAREs may be almost fully folded when the v-
SNARE is only half zippered. 
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 SNARE  scCPX/  
SNARE  
scCPX-F34M/ SNARE  
space group  P 1  C 21  P 1  
unit cell  a [Å]  27.6 75.9 53.7 
 b [Å]  39.8 52.7 127.4 
 c [Å]  102.3 128.7 142.7 
 α [°]  83.4 90 107.5 
 β [°]  89.9 95.2 90.0 
 γ [°]  89.9 90 90.1 
Resolution [Å] * 50-2.2  (2.28-2.2 )  50-3.5  (3.63-3.5)  30-3.8  (3.94-3.8)  
Unique reflections *
#
  20205  (1655)  6129  (576)  58784  (4948)  
Redundancy * 3.7  (3.3)  3.4  (3.5)  1.9  (1.8)  
I/σ * 19.7  (5.7)  15.7  (6.2)  9.1  (2.6)  
Completeness [%] *
#
  91.9  (76.4)  94.8  (91.3)  83.5  (80.7)  
Rsym [%] * 5.2  (20.4)  6.2  (23.4)  8.0  (25.3)  
Refinement [Å] 50-2.2 25-3.5 30-3.8 
Rwork / Rfree [%] 22.7 / 26.8 27.0 / 31.6 30.3 / 34.6 
rmsd bond  distances [Å] 0.017 0.054 0.035 
rmsd bond angles [°] 1.58 1.28 0.98 
mean B value [Å²]  56.9 99.8 116.1 
Ramachandran diagram [%] 
§
     
    most favored 98.8 91.7 98.4 
    additionally allowed 0.2 8.3 1.6 
Table	  1:	  Data	  processing	  and	  refinement	  statistics	  for	  the	  structures	  presented	  in	  this	  study.	  	  *	  values	  in	  parenthesis	  refer	  to	  outer	  shell	  of	  reflections	  	  #	  for	  reflections	  with	  I/σ	  greater	  than	  zero	  	  §	  from	  Molprobity57
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Figure	  17:	  Structure of the pre-fusion CPX/SNARE complex. VAMP2 (residues 29-60) is blue, syntaxin 
yellow (residues 190-250), SNAP25 lime (N-terminal SNARE motif, residues 10-74) and green (C-
terminal SNARE motif, residues 141-203) and CPX (residues 26-73) cyan. Model of (A) the truncated 
SNARE complex without and (B) with CPX bound. CPXcen is cyan, and CPXacc pale cyan. A dashed arrow 
indicates syntaxin membrane anchor. (C) Comparison of pre- and post-fusion CPX/SNARE complexes, 
with post-fusion CPX magenta (CPXacc is pale magenta, PDB ID 1KIL). The arrow indicates the 
conformational change of CPX during clamp release. (D) Top and side views of the zig-zag array of post-
fusion CPX/SNARE complexes observed in crystals. SNAREpins are related by 180° rotation and 
translation along the zig-zag midline, so that on different sides of the mid-line the linkers that connect 
syntaxins and VAMPs to their trans-membrane helices are on opposite sides of the zig-zag plane.	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We next co-crystallized SNAREΔ60 with a CPX fragment (scCPX) consisting of 
its central and accessory helices (residues 26-83) and containing three “superclamp” 
mutations (D27L, E34F, R37A) that increase its clamping efficiency both in vitro19 and 
in vivo39. The energy profile associated with clamping and clamp release is not altered, 
except that the superclamp binds more tightly to the pre-fusion SNARE complexes28. The 
structure was determined at 3.5 Å resolution using the truncated SNARE complex as a 
search model in the molecular replacement method (Table 1), and CPX was modeled into 
difference electron density. The final model includes residues 190-250 of syntaxin1, 10-
74 and 141-203 of SNAP25, 29-60 of VAMP2, and 26-73 of CPX (Figure 17B). 
To confirm the sequence alignment along CPX, we used selenomethionine 
substituted forms of scCPX, where residues L27 and F34 in the accessory helix were 
mutated to methionine (scCPX-L27M, scCPX-F34M). The selenomethionine-substituted 
forms of CPX were co-crystallized with the truncated SNARE complex, and anomalous 
data (Table 1) were used to calculate difference maps that unambiguously locate the 
position of residues 27 and 34 as well as 55, a methionine in the wild-type sequence 
(Figure 18). We also determined the structure of the selenomethionine-substituted 
scCPX-F34M bound to the truncated SNARE complex (Table 1). While the crystals of 
this complex belong to a different spacegroup (P1) from the scCPX/SNARE crystals we 
initially obtained (C2), our findings regarding CPX-SNARE interactions are similar.  
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Figure	  18:	  Electron density for CPX contoured at 1σ. (A) Weighted 2fo-fc electron density after 
refinement and (B) composite simulated annealed omit map for CPX in the C2 crystal form. (C) Weighted 
2fo-fc electron density after refinement (D) and four-fold averaged composite simulated annealed omit map 
for CPX-F34M in binding mode A of the P1 crystal form. (E) Weighted 2fo-fc electron density after 
refinement (F) and four-fold averaged composite simulated annealed omit map for CPX-F34M in binding 
mode B of the P1 crystal form.  There are two binding modes for CPXacc-F34M and the t-SNARE groove in 
the P1 crystal form, “A” and “B”. CPX and especially its accessory helix have high B-factors, and as seen 
in (A-F), solvent-exposed side-chains are not well ordered.  We therefore used selenomethionine-
substituted forms of CPX to confirm the sequence register. The anomalous difference maps used to located 
the positions of M55 and M34 are shown in orange in (D) and (F) and are contoured at 3.5 σ. (G) B-factor 
plot of CPX/SNARE complex in rainbow color scheme (blue to red, 17-185 Å2). 	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The CPX/SNAREΔ60 structures resemble the fully-zippered, post-fusion 
structures observed previously in several aspects (Figure 17C). The conformations of the 
SNARE proteins are essentially unaltered (rmsd 0.83 Å). Further, as in the post-fusion 
forms of the CPX/SNARE complex29,30 as well as alone in solution40, CPX forms a 
continuous helix. The interactions between CPXcen and the SNARE complex observed in 
the post-fusion structure are also largely unperturbed (small positional shifts in CPXcen 
are detailed in Table 2; see also Figure 17C). CPXcen binds in the groove between 
syntaxin1 and VAMP2, with key residues R59, R63, I66, Y70, and I72 inserted into two 
high affinity binding pockets observed in earlier studies29,30. A third previously identified 
binding interface involves residues D64, D65 and D68 in the VAMP2 C-terminus, which 
are missing in our construct. This interaction is not necessary for clamping41, and so its 
absence in our structure likely will not affect conclusions regarding the CPX clamping 
mechanism.  
  

















Table	  2:	  The	  central	  helix	  of	  Complexin	  is	  slightly	  differently	  anchored	  to	  the	  SNARE	  complex.	  	  The	  displacement	  for	  each	  Cα	  atom	  between	  the	  post-­‐fusion	  and	  pre-­‐fusion	  structure	  is	  listed. 
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Despite these similarities, the arrangement of CPX relative to the SNAREs in our 
structure differs markedly from that in post-fusion forms of the CPX/SNARE complex. 
The accessory helix undergoes a dramatic reorientation (rmsd of CPX as compared to 
PDB ID 1KIL30 is 2.2 Å). Rather than running alongside the SNARE complex, CPXacc 
now bends away at a ~ 45º angle (Figure 17C).  The reorientation likely results from 
small differences in CPXcen docking (Table 2) as well as small changes in phi/psi torsion 
angles in the transition region between CPXcen and CPXacc (Table 3). This result was 
unexpected given biochemical data indicating that CPXacc  should occupy the binding site 
for the VAMP2 C-terminus, since CPX and the VAMP2 C-terminus compete for binding 
to the t-SNAREs19,35. While CPXacc does not interact with the same SNARE complex 
bound by CPXcen, however, it does interact with a second, symmetry-related complex. 
Overall, the crystal packing is such that CPX/SNARE complexes are arranged in 
a continuous zig-zag (Figure 17D), leaving the middle of the accessory helix entirely 
solvent exposed. This region has high thermal motion, as evidenced by high B-factors 
(Figure 18). SNAREpins on opposite sides of the zig-zag mid-line are related by a 180 
degree rotation about (and a translation along) the mid-line. This means that on different 
sides of the mid-line, the linkers that connect the syntaxins and the VAMPs to their trans-
membrane helices in the plasma membrane and the synaptic vesicle, respectively, are on 
opposite sides of the zig-zag plane. Although the CPX-F34M mutant crystallized in a 
different space group, it cross-links different SNARE complexes the same way, and the 
complexes are arranged in a zig-zag (Figure 19).  
 	   	   	   	  
102 
CPX Post-fusion Pre-fusion Difference 
position phi [°] psi [°] phi [°] psi [°] phi [°] psi [°] 
45 -77.4 -35.2 -83.4 -36.1 6.0 0.9 
46 -63.1 -27.8 -72.3 -31.8 9.2 4.0 
47 -86.1 -35.4 -75.3 -49.5 -10.8 14.1 
48 -65.4 -39.4 -54.2 -31.6 -11.2 -7.8 
49 -68.7 -30.4 -69.1 -43.4 0.4 13.0 
50 -73.3 -43.5 -65.9 -41.7 -7.4 -1.8 
51 -64.9 -26.0 -62.3 -38.7 -2.6 12.7 
52 -90.0 -19.9 -68.1 -33.2 -21.9 13.3 
53 -78.2 -35.6 -63.4 -45.4 -14.8 9.8 
54 -68.3 -35.9 -73.3 -35.0 5.0 -0.9 
55 -65.2 -44.9 -66.3 -40.9 1.1 -4.0 
56 -59.5 -47.4 -54.8 -54.8 -4.7 7.4 
57 -58.2 -43.9 -54.2 -40.6 -4.0 -3.3 
58 -63.1 -33.9 -82.4 -14.2 19.3 -19.7 
average -70.1 -35.7 -67.5 -38.4 -2.6 2.7 
Table	  3:	  The	  CPX	  helix	  twisted	  differently	  in	  the	  post-­‐	  and	  pre-­‐fusion	  structure.	  	  Peptide	  angles	  of	  the	  CPX	  region	  linking	  the	  central	  and	  accessory	  helix	  are	  listed. 
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Figure	  19:	  Zig-zag arrays in the P1 crystal form. (A) Superposition of CPX/SNARE complexes 
constituting four crystallographically distinct zig-zag arrangements in the P1 crystal form. (B)-(E) Top and 
side view of the four different lattices in the P1 crystal form.	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Overall, the crystal packing is such that CPX/SNARE complexes are arranged in 
a continuous zig-zag (Figure 17D), leaving the middle of the accessory helix entirely 
solvent exposed. This region has high thermal motion, as evidenced by high B-factors 
(Figure 18). SNAREpins on opposite sides of the zig-zag mid-line are related by a 180 
degree rotation about (and a translation along) the mid-line. This means that on different 
sides of the mid-line, the linkers that connect the syntaxins and the VAMPs to their trans-
membrane helices in the plasma membrane and the synaptic vesicle, respectively, are on 
opposite sides of the zig-zag plane. Although the CPX-F34M mutant crystallized in a 
different space group, it cross-links different SNARE complexes the same way, and the 
complexes are arranged in a zig-zag (Figure 19). 
Residues at the N-terminal end of CPXacc (L27, A30, A31, F34, and A37) form a 
hydrophobic surface which binds to the t-SNARE in a second SNARE complex in a site 
normally occupied by the C-terminus of the VAMP2 helix in post-fusion state, which was 
deleted from the mimetic used here (Figure 20A, Figure 21). In crystals of scCPX-
F34M/SNARE, the interactions between CPXacc and the t-SNARE groove are as just 
described for the scCPX/SNARE crystals in four of eight crystallographically distinct 
complexes. In the remaining four complexes, the binding site on the t-SNARE is shifted 
by approximately two helical turns, so that the interface between CPXacc and the t-
SNARE is larger (~1000 Å2 versus ~715 Å2, Figure 20B, Figure 21), additionally 
involving CPX residues L41, A44 and R48. Because a single mutation in the CPXacc 
sequence allows for two different binding modes, we expect that the high sequence 
variability in CPXacc of different complexins (isoforms 1-4 and in different organisms) 
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results in slight variations of SNARE-bridging interactions and strength. The recurrence 
of the zig-zag arrangement of CPX/SNARE complexes in two different crystal forms, 
however, supports the notion that this arrangement may be physiologically relevant. 
Notably, for both scCPX and scCPX-F34M, residues that were mutated to make 
the superclamp CPX (D27L, E34F/M, R37A) are an integral part of the hydrophobic 
interface with the SNARE complex. The ability to bind the t-SNARE surface via a more 
extended hydrophobic interface may explain why the superclamp sequences have a 
higher affinity for pre-fusion SNARE complexes than wild-type CPX (shown below) and 
why superclamp CPXacc clamps more effectively in vitro and vivo19,39.  
SOLUTION STUDIES CONFIRM THE CPXACC/SNAREΔ60 INTERACTION. 
Thus, in both the CPX/SNARE structures, we find CPXacc interacting with the t-
SNAREs in such a way that CPX, linked by its central helix to one SNARE complex, 
blocks binding of the VAMP2 C-terminus to another complex, cross-linking the SNARE 
complexes into an array in the process.
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Figure	  20:	  Interacting surfaces of CPXacc and the t-SNAREs. (A) Interacting residues of scCPX are 
labeled in left panels; the binding site on the t-SNARE is outlined as grey patch and labeled on right panels. 
(B) For scCPX-F34M, CPXacc can bind to the t-SNARE groove as in (A) or as shown here. (C) Sequence of 
the accessory helix of wild-type (wt) CPX and the non-clamping (nc) and superclamp (sc) mutants. 
Residues of CPX interacting with the t-SNARE in the crystal structures are boxed. The side chain of K26 is 
disordered in our structure, but functional data19 suggest that it has a role in clamping. It may interact with 
the VAMP2 C-terminus absent in our structure.	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Figure	  21:	  Comparison	  of	  the	  hydrophobic	  layer	  interactions	  of	  the	  t-­‐SNARE	  groove	  with	  VAMP2	  (left	  panels)	  CPX	  in	  binding	  mode	  A	  (middle	  panels)	  and	  in	  binding	  mode	  B	  (right	  panels).	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We used isothermal titration calorimetry (ITC) experiments to confirm that 
CPXacc interacts with the t-SNARE in pre-fusion SNARE complexes. In these 
experiments, we used a complexin construct comprising both the central and  accessory 
helices (residues 26-83) rather than a peptide corresponding to the accessory helix alone. 
Our rationale was that the accessory peptide does not fold into an alpha helix, as 
monitored by CD, and thus does not fold as in the full length protein, where it has high 
helical propensity (CD and ref. 40). The longer complexin construct was chosen to avoid 
complications in binding measurements resulting from folding energetics. To observe the 
interaction between only CPXacc and the SNARE complex, we blocked the CPXcen 
binding site on either a fully-assembled post-fusion SNARE or SNAREΔ60 by pre-
binding CPXcen (residues 48-134). Various CPX constructs were then titrated in to derive 
interaction affinities. As predicted from the post-fusion SNARE/CPX crystal structure, 
we find no additional interaction between wild-type complexin (wtCPX, residues 26-83) 
and the blocked post-fusion SNAREpin (Figure 22A). In contrast, wtCPX interacts with 
blocked SNAREΔ60 with Kd ~10 µM affinity, consistent with an additional binding site 
present only pre-fusion and the finding that CPX competes with the VAMP2 C-terminus 
for binding19. Further, the interaction affinity can be modulated by mutating residues in 
CPXacc, as expected if CPXacc participates in the interaction (Figure 22B). We used CPX 
mutants where residues at the CPXacc/SNARE interface in the crystal structure were 
altered. In addition to scCPX (D27L, E34F, R37A) we designed a non-clamping CPX 
mutant (ncCPX: A30E, A31E, L41E, A44E), where hydrophobic residues at the 
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CPXacc/t-SNARE interface in the crystal structure were replaced by charged residues 
(Figure 20C). As expected, the binding affinity for scCPX is ~8-fold stronger than wild-
type, consistent with the difference in activity observed in both in vitro and in vivo 
assays19,39, whereas ncCPX no longer interacts with blocked SNAREΔ60 (Figure 22B). 
Thus, binding studies corroborate an interaction between CPXacc – both wild-type and 
superclamp – and the pre-fusion SNARE complex as observed in the crystal structure. 
We used Förster resonance energy transfer (FRET) experiments to establish that 
the angled conformation of CPX also occurs in solution and therefore is not dictated by 
crystal packing. The donor dye (stilbene) was attached to SNAP-25 residue 193, with the 
acceptor dye (bimane) positioned either at residue 31 or 38 of superclamp CPX (Figure 
23A). (Note that acceptor positions are placed so that they would interfere with CPXacc/t-
SNARE cross-linking interactions, enabling monodisperse CPX/SNARE complexes to be 
studied.) Distances estimated via quenching of donor fluorescence for CPX bound to the 
fully zippered SNARE complex correspond closely to distances observed in the crystal 
structure of the post-fusion CPX/SNARE complex (PDB 1KIL), where CPXacc runs 
parallel to the SNARE complex (Figure 23B,C, Table 4).  
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Figure	  22:	  Characterization of the interaction of CPXacc with SNARE complexes by isothermal titration 
calorimetry. (A) A groove in the t-SNARE is a second binding site for CPX distinct from the central helix 
binding site. When the central helix binding site on the SNARE complex is blocked, CPX still binds to the 
SNARE complex once the C-terminal half of VAMP2 is removed in the pre-fusion SNARE mimetic. (B) 
Binding to the t-SNARE groove is mediated by CPXacc. Mutations in the accessory helix of CPX modulate 
the binding affinity to the t-SNARE positively (scCPX) or negatively (ncCPX) as expected from the crystal 
structure.	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Figure	  23:	  FRET experiments probing CPX orientation in pre- and post-fusion CPX/SNARE complexes. 
(A) Superposition of pre- and post-fusion CPX/SNARE complexes, where pre-fusion CPX is cyan and 
post-fusion CPX is pale cyan. As indicated (magenta), SNAP25 was labeled with stilbene at position 193, 
and CPX was labeled with bimane at positions 31 or 38. (B) Fluorescence emission spectra of stilbene only 
(black) and stilbene/bimane labeled CPX/SNARE complexes containing VAMP2 (residues 25-96, red), 
VAMP2-Δ60 (residues 25-60, green), or VAMP2-4X (residues 25-96 with mutations L70D, A74R, A81D, 
L84D to preclude zippering of the VAMP2 C-terminus, blue). CPX is labeled with bimane at residue 38. 
(C) As in (B), but CPX is labeled with bimane at residue 31. These data were used to calculate distances 
shown in Table 2. (D) FRET of a “flexible” CPX mutant (CPX-GPGP) in comparison to wt CPX when 
bound to pre-fusion (VAMP2-Δ60) or post-fusion (VAMP2) SNARE complexes. When the accessory helix 
is uncoupled from the central helix by a helix-breaking GPGP insertion, there is a complete loss of FRET 
signal with both SNARE complexes, different from the partial change in FRET observed with intact CPX. 
Thus, it is unlikely that differences between the FRET signals observed with intact CPX are due to random 
motion in CPXacc.	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 Distance* SNAP25-193 to  
CPX-38 [Å] CPX-31 [Å]  
FRET measurements    
VAMP2 (25-96)  20 ± 1   27 ± 1  
VAMP2-D60 (29-60)  34 ± 1  42 ± 1  
VAMP2-4X (25-96; 
L70D,A74R,A81D,L84D)  
33 ± 1   38 ± 1 
Measured in crystal structure    
post-fusion (PDB 1KIL)  18 24 
pre-fusion (C2 crystal form)  28 38 
* Error bars reflect the reproducibility of the spectra rather than accuracy of the 
distance measurements. 
Table	  4:	  FRET	  distances	  were	  determined	  from	  quenching	  of	  donor	  fluorescence	  between	  SNAP25	  and	  CPX	  when	  bound	  to	  SNARE	  complexes	  in	  post-­‐fusion	  (VAMP2)	  or	  pre-­‐fusion	  (VAMP2-­‐Δ60,	  VAMP2-­‐4X)	  conformation.	  	  Error	  bars	  refer	  to	  n	  =	  4-­‐6	  independent	  experiments.	  	  Values	  measured	  in	  the	  respective	  crystal	  structures	  are	  given	  for	  comparison. 	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In contrast, residues nearer the CPXacc N-terminus appear to move increasingly 
away from the SNARED60 complex used for crystallization (so that the dye at CPX 
residue 31 is farther from the donor than the dye at CPX residue 38) and the distances 
estimated via quenching of donor fluorescence (see Figure 24 for comparable data for 
acceptor fluorescence increase and with a second FRET pair) agree with the angled 
conformation in the crystal structure (Table 4, Figure 23B,C). Use of a “flexible” CPX 
construct (CPX-GPGP), where a helix-breaking GPGP linker was inserted between the 
central and accessory helices of CPX, discounts the possibility that the change in the 
FRET signal reflects random motion in CPXacc due to increased CPX flexibility rather 
than a discrete change in CPX conformation (Figure 23D). In contrast to the experiments 
with the undisrupted CPX constructs, there was no detectable FRET signal for CPX-
GPGP bound to either SNARED60 or to the post-fusion SNARE, consistent with random 
motion in CPX-GPGP but not for the intact CPX. To rule out that the angled 
conformation in solution results from VAMP2 truncation, we also studied and obtained 
similar results (Table 4, Figure 23B,C) for a complex containing the entire VAMP2 
SNARE motif, but harboring mutations in its C-terminal hydrophobic layers (L70D, 
A74R, A81D, L84D) that prevent assembly of this region with syntaxin1 and SNAP25 
and eliminate fusion activity41. These experiments indicate that when bound to a half-
zippered form of the SNARE complex, it is the intrinsic property of CPXacc to extend 
away from the complex. Because this conformation is maintained in solution, it 
determines how the complex crystallizes, and not vice versa.  
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Figure	  24:	  (A) Increase in the acceptor (Bimane) signal correlates with quenching of the donor (Stilbene) 
fluorescence confirming FRET. Acceptor (Bimane) emission was extracted from the Stilbene/Bimane 
emission scans (Figure 23) by subtracting the donor and buffer contributions. The corrected acceptor 
emission was then normalized with maximum acceptor fluorescence when excited at acceptor excitation 
wavelength (396 nm). We observe more FRET with the VAMP2 (residues 25-96) than with VAMP2-Δ60 
(residues 25-60), with both CPX labeled on 38 (black vs. green, respectively) and 31 (red vs. blue, 
respectively) which shows that the CPXacc helix is further away from the SNAREpin in the pre-fusion 
(VAMP2-Δ60) complex than the post-fusion VAMP2 (residues 25-96) complex. The acceptor fluorescence 
increase qualitatively matches the donor-quenching data except for CPX labeled at position 38 in the 
CPX/SNARE complex containing VAMP2. However, the acceptor emission is 1/3 weaker in this complex 
compared to the other CPX/SNARE complexes, even though the excitation properties are unaffected. This 
means the local environment possibly affects the acceptor emission in this case and could explain the 
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anomalous behavior. (B) Fluorescence emission spectra of Bimane alone (black), only Oregon green (red), 
and Bimane/Oregon labeled CPX/SNARE complex containing VAMP2 (residues 25-96, green), VAMP2-
Δ60 (residues 25-60, blue) excited at 396 nm. SNAP25 D193C was labeled with donor, Bimane, and CPX 
was labeled with acceptor, Oregon green 488, at positions 38 (left panel) or 31 (right panel). The FRET 
measurements from this FRET pair are in good agreement with  the results obtained with the 
Stilbene/Bimane FRET pair (Figure 23), confirming that the CPXacc helix bends away from the SNAREs in 
the truncated SNARE complex compared to the fully-zippered SNARE complex. (C) Bleaching of acceptor 
(Oregon green) fluorescence results in donor (Bimane) fluorescence increase demonstrating FRET. 
Fluorescence recovery (FRAP) experiments were done on Bimane/Oregon labeled CPX/SNARE 
complexes containing VAMP2 (residues 25-96, black) or VAMP2-Δ60 (residues 25-60, red) in a Leica SP5 
confocal setup. The acceptor fluorescence was bleached using a 488 nm laser and the fluorescence recovery 
was recorded in two different channels set at 440-480 nm (Bimane, filled symbols) and 500-540 nm 
(Oregon green, open symbols) respectively.  The fluorescence intensity normalized with respect to the pre-
bleach fluorescence is shown above. There is an increase of the donor fluorescence after bleaching of the 
acceptor and the effect is larger for VAMP2 compared to VAMP2-Δ60. This means CPXacc helix is closer 
to the SNAREpin in the CPX/SNARE complex containing VAMP2 than in VAMP2-Δ60 complex 
corroborating our previous results.	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Thus, as CPX rigidly extends away from the half-zippered SNARE complex, the 
only plausible way for both its central and accessory helices to interact with the 
SNAREpin is if CPX can interact with two different pre-fusion SNAREs, cross-linking 
SNAREs into an array like the zig-zag observed in the crystals. 
MUTATIONS IN THE CPXACC BINDING SURFACE AFFECT CLAMPING. 
Further support that the CPXacc/t-SNARE binding interface observed in the crystal 
structure represents biologically relevant interactions comes from in vitro clamping 
assays. In these experiments, “flipped” SNARE proteins are expressed on the cell 
surface, and the effects of CPX and synaptotagmin constructs on cell-cell fusion are 
monitored. These flipped-SNARE cell-cell fusion assays were initially developed to 
demonstrate clamping by CPX and clamp release by synaptotagmin4,18 and the effects of 
CPX mutations (including the superclamp mutations) in these assays are consistent with 
their effects in vivo39.  
We systematically tested the effect of the mutations introduced in CPXacc and 
mapped residues that do or do not affect clamping onto the surface of CPX (Figure 
25A,B). Mutations which are located at the CPXacc/SNARE interface observed in the 
structure all alter clamping efficiency. As expected, clamping is affected positively by 
scCPX mutations and negatively by ncCPX mutations (Figure 25). As a control, 
mutations that are oriented away from the interface on the opposite side of CPX have no 
effect on clamping (Figure 25). These findings strongly support that the interface 
observed in the crystal contact is relevant for the physiological function of complexin and 
verify the rational of our mutant design for ITC. 
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Figure	  25:	  Effects of CPX and VAMP2 mutations on clamping in cell-cell fusion assays. (A) Mutational 
analysis of CPX accessory helix mutations in the cell-cell fusion assay. (B) Mapping of the mutational 
analysis of the CPXacc/t-SNARE interface. CPXacc is shown with the surface that interacts with the t-
SNARE in the crystal structures outlined in black. Mutations in CPX that affect clamping positively (green) 
or negatively (red) are at the interface. Mutations that do not affect clamping (blue) are on the opposite side 
of CPX. (C) Location of the helix breaking mutations (magenta) between central and accessory helix in the 
CPX/SNARE pre-fusion crystal structure.	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We note, however, that although ITC and the in vitro clamping assays validate 
that CPXacc interacts with pre-fusion t-SNAREs using a surface similar to that identified 
from the crystal structure, it is likely—given the differences between the superclamp and 
wild-type sequences—that the details of the interaction differ for wild-type CPX. But as 
discussed earlier, due to low sequence conservation in the accessory helix, there may be 
also variability in the interactions of CPXacc from different organisms. 
The observations from the crystal structure and their agreement with FRET from 
mono-disperse solutions suggest that the CPX accessory helix rigidly bends away from 
the SNARE complex. To test whether the rigidity of CPX is important for clamping, we 
again used the flipped SNARE cell-cell fusion assays. We used CPX mutants (CPX-
GPGP, CPX-GGG) which had a helix-breaking linkers (GPGP and GGG, respectively) 
inserted after residue 50, between CPXcen and CPXacc, as well as a construct where 
residues 51-53 at the central-accessory helix junction were replaced by glycines to disrupt 
the long CPX helix (see Figure 25C). Clamping should be affected if the continuity and 
hence rigidity of the CPX helix is mechanistically important. We found that clamping 
indeed was reduced in all three cases, consistent with the requirement for a continuous 
helix (Figure 25A). 
MODEL FOR CLAMPING 
Binding, fluorescence and functional studies all corroborate the conformation of 
CPX as observed in the crystal structure as well the novel interaction identified between 
CPXacc and the t-SNARE. Based on the crystal structure, we therefore propose that CPX 
directly cross-links pre-synaptic, pre-fusion SNARE complexes and further that the 
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arrangement of CPX/SNARE complexes in the clamped state is similar to the zig-zag 
observed in the crystal lattice. Such an arrangement is plausible given the length of 
linkers that anchor the t- and v-SNAREs to the membranes, as the linkers for syntaxin1 
and the half-zippered VAMP2 are longer than 10 (~ 37 Å) and 30 residues (>100 Å), 
respectively (Figure 26A). The number of CPX/SNARE complexes in the zig-zag would 
be limited due to curvature in the vesicle, which increases the distance between the 
vesicle and plasma membranes with increasing distance from the fusion site (close to the 
zig-zag center), so that polymer extension beyond a certain distance is untenable. 
Experiments suggest that for optimal fusion rates, there are 5-10 SNARE complexes in a 
fusion pore14, allowed by our model.  
The crystal structure naturally suggests several synergistic mechanisms by which 
CPX might stabilize the pre-fusion state and inhibit fusion (Figure 26):  
First, CPXacc binds the t-SNAREs in a site occupied by C-terminal portions of the 
VAMP2 SNARE motif in post-fusion SNARE complexes, competitively blocking the 
completion of zippering by VAMP2 as proposed previously from biochemical 
studies19,35, but with the critical modification that this interaction occurs inter-
molecularly. 
Second, close apposition of SNAREpins by cross-linking at their zippering ends 
should prevent further zippering which, if it occurred would cause them to sterically clash 
(~2 turns of the N-terminal SNAP25 SNARE motifs are not folded in our structure).  
Third, the linker regions of Syntaxin1 and VAMP2 on different sides of the zig-
zag mid-line emerge on opposite sides of the zig-zag plane, again sterically interfering 
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with complete zippering. 
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Figure	  26:	  Molecular models for CPX clamping. (A) Model for the clamp at the synapse. CPX/SNARE 
complexes with half-zippered VAMP2 are cross-linked by CPX into a zig-zag topology incompatible with 
fusion (see text). The plane of the zig-zag is normal to the vertical direction. For clarity, only two of the 
CPX/SNARE complexes in the zig-zag are shown. Palmitoylation on SNAP25 is indicated and restrains the 
distance between the CPX/SNARE zig-zag and the plasma membrane (PM). The distance between the zig-
zag plane and the vesicle (SV) must be less than ~110 Å, the maximum distance spanned by the v-SNARE 
linker. The calcium sensor synaptotagmin (grey with Ca2+-binding loops orange), which relieves CPX 
clamping, is accommodated by this model and is positioned according to FRET analysis46. Its Ca2+-binding 
loops are juxtaposed to the vesicle membrane, which is rich in anionic lipids like phosphatidyl-serine 
(black), well positioned for interactions with this membrane in response to Ca2+ stimulus. (B) Model of the 
CPX/SNARE assembly in the clamped state when the fusion pore is “closed” (left). The fusion pore can 
open only once the zig-zag clamped array has disassembled (right). Complexes in “open” state are modeled 
on PDBID 1KIL.	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Fourth, the fusion pore cannot form as it is blocked by the CPX/SNARE zig-zag 
array, which is interposed between the vesicle and plasma membranes. Our finding from 
functional assays that flexibility in CPX interferes with clamping suggests that the 
CPX/SNARE zig-zag must be rigid at least to some extent. The requirement for rigidity 
is consistent with a role as a barrier between membranes that are poised for fusion. 
And fifth, cross-linking the SNARE complexes into a zig-zag prevents them from 
forming the circular arrangement needed to accommodate either a hemi-fusion stem42 or 
a fusion pore43, precluding their formation. Notably, though, even in the zig-zag, the 
orientation of the SNAREs is very similar to that in a fusion-competent arrangement 
(compare panels in Figure 26B), except that the cross-links must dissolve in order for 
fusion to take place. As the zig-zag clamp disassembles and SNAREs zipper, steric 
repulsion would push the SNAREs radially away from the zig-zag mid-line to form a 
circular arrangement (Figure 26B), now enclosing a nascent fusion pore which opens 
progressively as zippering completes44. 
Though clearly vital for clamping19, each pairwise interaction between CPXacc 
and t-SNARE complexes seems of relatively low affinity (Kd ~ 10 µM, corresponding to 
~6.8 kcal/mol). Nonetheless, binding with this affinity is likely to occur physiologically 
because the concentrations of CPX and SNARE proteins in the region local to fusion 
between apposed bilayers (~20 nm x ~20 nm x ~20 nm (Figure 26A) containing 5-10 
CPX/SNARE complexes14) are likely to be in the 1-2 mM range (incidentally, an order of 
magnitude higher than their concentration in the crystallization mixture). And due to 
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entropy considerations, polymerization would be more favored for proteins constrained to 
two dimensions, as at the synapse, than in solution.  
The clamp may be further stabilized by the CPX N-terminus, which is absent in 
our structure, and which can interact with membrane proximal portions of SNAREs20,45. 
And functional assays show that synaptotagmin (included in Figure 26A according to46), 
in its calcium-free conformation, stabilizes the clamped state produced by CPX18,47, 
although how this occurs is currently unclear.  
SNARE ACTIVATION 
As noted previously, in addition to its inhibitory role, CPX also has an important 
positive role in promoting fusion21,28. Some of the domains shown to be required for this 
mode of action21,24 are not present in our structure. It has been speculated, however, that 
one positive contribution may result from the binding of CPXcen to the VAMP2/syntaxin1 
interface, which would stabilize initial SNARE assembly and zippering27,30. Our studies 
now suggest a similar role for the accessory helix: its interaction with the t-SNARE 
groove newly identified by us indicates that CPX might facilitate t-SNARE folding by 
binding to the C-terminal part of their SNARE motifs prior to VAMP2 binding. 
Most importantly, we note that the assembled clamp itself might promote fusion 
by simply setting the stage: multiple SNARE complexes are gathered in orientations 
close to that required for fusion pore formation (compare panels in Figure 26B) even as 
their cross-linking impedes it, and they are already half-zippered. This alone will allow 
for fast, efficient fusion as soon as the clamp is released upon stimulus.  
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The mechanism of clamp disassembly is further explored in an accompanying 
manuscript41, as is the finding that clamp release is intrinsically coupled to a 
conformational change in CPX, where CPX switches from the angled conformation 
observed in the CPX/SNAREΔ60 structure to that in the post-fusion CPX/SNARE 
complex29,30. 
EXPERIMENTAL PROCEDURES 	  
PROTEIN EXPRESSION, PURIFICATION AND COMPLEX ASSEMBLY. 
Recombinant fusion proteins were expressed in E.coli BL21 (DE3) cells by 
induction with 0.5 mM IPTG for 4 h at 37 °C. Selenomethionine substituted CPX-L27M 
and CPX-F34M were expressed according to Doublie48. Proteins were purified with 
either glutathione-Sepharose (GE) or Ni-NTA-agarose (Qiagen) resin and tags were 
cleaved according to manufacturers’ instructions. Complexes were reconstituted by 
mixing proteins, followed by gel filtration on a HiLoad Superdex 75 (16/60, GE 
Healthcare). See Supplementary Methods for detailed protocols.  
CRYSTALLIZATION AND DATA COLLECTION. 
Peak fractions were pooled and concentrated to ~10 mg/ml for crystallization. 
Crystals were obtained at 20 °C using the hanging drop vapor diffusion method. The best 
crystals were obtained when the SNARE complex was mixed with 6-fold molar excess of 
CPXacc peptide (residues 26-35, purchased from Biosynthesis) and equilibrated against 
0.05 M calcium acetate, 27% 2-methyl-2,4-pentanediol (MPD), 0.1 M sodium cacodylate 
pH 6.5-7.0. The crystals were loop-mounted from the mother liquor and plunged into 
liquid nitrogen for cryopreservation. 
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Crystals of the CPX/SNARE complex were obtained by equilibration against a 
solution containing 13-15% polyethyleneglycol (PEG) 5000MME, 0.2 M ammonium 
sulfate, 0.01 M EDTA, and 0.1 M Tris pH 7.5. Crystallization conditions for the CPX-
L27M/SNARE and CPX-F34M/SNARE complexes were similar. Crystals were 
transferred into buffer supplemented with 15% PEG 400 prior to flash-freezing in liquid 
nitrogen.  
Data were collected at NSLS (National Synchrotron Light Source, Brookhaven) 
beamline X29 and APS (Advanced Photon Source, Argonne) beamline ID-24C processed 
with HKL200049.  
STRUCTURE DETERMINATION 
For all crystals, phases were obtained by the molecular replacement method as 
implemented in Phaser50. Models were build in Coot51 and refined with Refmac52. For the 
truncated SNARE complex we used a search model based on PDB 1KIL. TLS groups 
and non-crystallographic symmetry (NCS) restraints were used in refinement and led to a 
high resolution model of the truncated SNARE complex. The CPXacc peptide (26-35) in 
the crystallization solution is not bound to the SNARE complex. 
Crystals of the CPX/SNARE complex belong to space group C2 and diffract to 
3.5 Å resolution. The truncated SNARE complex served as the search model. Complexin 
was manually built into difference density as a continuous α-helix. For refinement, TLS 
groups and H-bond restraints for α-helical secondary structure derived from the high 
resolution SNARE complex structure were used.  
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The selenomethionine substituted CPX-F34M/SNARE crystals diffract to 3.8 Å 
resolution. The crystals have P21 pseudosymmetry but we were able to refine to 
reasonable R values only in P1. As there are eight CPX-F34M/SNARE complexes in the 
P1 asymmetric unit, we used the thin shell method in choosing the Rfree set in order to 
avoid bias from non-crystallographic symmetry (NCS)53. The truncated SNARE complex 
structure was used as a search model in molecular replacement. A Fourier anomalous 
difference map was calculated using CNS54, allowing us to unambiguously locate the 
positions of the Se atoms of residues 34 as well as 55, a methionine in the wild-type 
sequence in CPX-F34M. NCS restraints were used in refinement.  
Composite simulated-annealed omit maps were calculated in CNS54 to confirm 
the CPX/SNARE models (Figure 18). 
Crystals of the selenomethionine substituted CPX-L27M/SNARE complex belong 
to space group P1 and diffract to 4.5 Å. A molecular replacement solution using the 
CPX/SNARE complex as search model was found, identifying 4 complexes in the 
asymmetric unit. Although data resolution did not allow us to refine the structure, we 
could determine the position of the CPX Se atoms of residues 27 and 55, a methionine in 
the wild-type sequence, in an anomalous difference map calculated using phases from the 
molecular replacement solution54. The positions are consistent with register in the 
CPX/SNARE complex. 
All figures were prepared with Pymol55. Data collection and refinement statistics 
are summarized in Table 1. 
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ISOTHERMAL TITRATION CALORIMETRY (ITC) ANALYSIS. 
The ITC analysis is described in more detail in the Supplementary Methods. 
Briefly, measurements were carried out with a Microcal ITC200 instrument. Proteins 
were in PBS buffer supplemented with 0.25 mM TCEP. The CPX constructs (200-600 
µM) were titrated into a solution of SNARE complexes in the sample cell (10-30 µM), 
and thermodynamic parameters were calculated using the Microcal Origin ITC200 
software package and assuming a “one-set-of-sites” binding model. 
FRET ANALYSIS. 
Positions D193 on SNAP25 and Q38 or A31 on scCPX (hCpx1 residues1-134 
carrying superclamp mutations D27L, E34F and R37A) were mutated into cysteines 
using the Stratagene QuikChange Kit. SNAP25 D193C was labeled with the donor probe, 
Stilbene (4-acetamido-4’-((iodoacetyl)amino)-stilbene-2,2’-disulfonic acid, disodium 
salt, Invitrogen) and either CPX Q38C or A31C was labeled with the acceptor Bimane 
(Monochlorobimane, Invitrogen), using 10X molar excess of dye overnight at 4°C in 50 
mM Tris Buffer, pH 7.4, containing 150 mM NaCl, 10 % Glycerol and 1 mM TCEP. 
Excess dye was separated from the labeled proteins using a NAP desalting column (GE 
Healthcare). The double-labeled CPX/SNARE complexes were assembled overnight at 
4°C and purified by gel-filtration on a Superdex 75 (10/30, GE Healthcare) gel filtration 
column. All fluorescence data were obtained on a Perkin-Elmer LS55 luminescence 
spectrometer at 25°C. Excitation and emission slits of 5 nm were used in all 
measurements. Fluorescence emission spectra were measured over the range of 350-550 
nm with the excitation wavelength set at 335 nm. The donor probe concentration was 
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adjusted to 2 µM in all samples. We used fluorescence resonance energy transfer (FRET) 
to calculate the distance between the two fluorophores with a R0 of 27.5 Å for the 
Stilbene-Bimane FRET pair56. See Supplementary Methods for more detailed 
experimental procedures.  
CELL-CELL FUSION ASSAY. 
The flipped SNARE cell-cell fusion assay was performed as described 
before4,18,19,31. In brief, HeLa cell lines were transiently transfected with flipped VAMP2 
(wt or 3xDA), DsRed2-NES and either with or without CPX mutants and synaptotagmin 
as indicated (v-cells). After one day, transfected v-cells were seeded onto glass coverslips 
containing cells stably co-expressing flipped syntaxin1, flipped SNAP-25 and CFP-NLS 
(t-cells). The following day, cells were fixed with 4% paraformaldehyde directly or after 
treatment with recovery solution (1 U/ml Phosphatidylinositol Specific Phospholipase-C, 
20 µg/ml laminin, with or without 1.8 mM EGTA), washed and mounted with Prolong 
Antifade Gold mounting medium (Molecular Probes). Confocal images were acquired on 
a Zeiss 510-Meta confocal microscope and processed using Adobe Photoshop software. 
ACCESSION CODES 
Coordinates and structure factors for the structures described in this manuscript 
have been submitted to the PDB (accession codes XXXX and YYYY). 
ADDITIONAL DATA 	   This	  paper	  contains	  data	  on	  a	  helix-­‐breaking	  motif	  without	  demonstrating	  that	  the	  motif	  actually	  disrupts	  the	  helicity	  of	  the	  Complexin.	  	  Here	  I	  present	  circular	  dichroism	  (CD)	  data	  which	  demonstrate	  that	  this	  is,	  in	  fact,	  the	  case.	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Figure	  27:	  Circular	  Dichroism	  data	  shows	  that	  the	  insertion	  of	  helix	  breaking	  motifs	  between	  the	  Central	  and	  Accessory	  Helices	  in	  Complexin	  actually	  does	  disrupt	  the	  helices.	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SUPPLEMENTARY EXPERIMENTAL PROCEDURES 	  
PROTEIN EXPRESSION, PURIFICATION AND COMPLEX ASSEMBLY. 
Recombinant fusion proteins were expressed in E.coli BL21 (DE3) cells by 
induction with 0.5 mM IPTG for 4 h at 37 °C. The constructs used for crystallization are 
GST-PreScission-VAMP2Δ60 (containing human VAMP2 residues 29-60), GST-TEV-
syntaxin1A (containing rat syntaxin1a residues 191-253), oligohistidine-MBP-Thrombin-
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SNAP25N (containing human SNAP25A residues 7-82 and a C-terminal tryptophan), 
GST-TEV-SNAP25C (containing human SNAP25A residues 141-203) and GST-
PreScission-CPX (containing human complexin1 residues 26-83 with the following 
“superclamp” mutations: D27L, E34F, R37A). To make CPX-L27M and CPX-F34M, 
positions 27 or 34 of CPX were mutated to methionine using QuikChange mutagenesis 
(Stratagene). 
Cells were harvested and resuspended in buffer S (140 mM NaCl, 1 mM DTT, 20 
mM Tris pH 7.5) supplemented with protease inhibitors (Complete EDTA-free, Roche), 
DNaseI (Sigma) and lysozyme (American Bioanalytical), then lysed using a cell disruptor 
(Avestin).  Proteins were purified with either glutathione-Sepharose (GE) or Ni-NTA-
agarose (Qiagen) resin according to manufacturers’ instructions. Tags were cleaved with 
TEV, PreScission or thrombin (Sigma) protease overnight at 4 °C. The proteins were 
collected, concentrated and purified by size exclusion chromatography on a HiLoad 
Superdex 75 (16/60, GE Healthcare) column equilibrated with buffer S. 
Selenomethionine substituted CPX-L27M and CPX-F34M were expressed according to 
Doublie 48 and purified as described above.  
To reconstitute the truncated SNARE complex, VAMP2-Δ60, SNAP25C, 
SNAP25N and synatxin1 were mixed at 1:1:1:1 molar ration and incubated for 2 h before 
gel filtration on a HiLoad Superdex 75 (16/60, GE Healthcare) column equilibrated with 
buffer S. CPX was added to the truncated SNARE complex at 1.2 molar excess and 
incubated over night. The sample was supplemented with imidazole (20 mM final 
concentration) and passed over 0.5 ml Ni-NTA resin three times to remove TEV and 
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PreScission proteases, which are oligohistidine tagged. The mixture was loaded on a 
HiLoad Superdex 75 (16/60, GE Healthcare) column equilibrated with buffer S, and peak 
fractions were pooled and concentrated to ~10 mg/ml for crystallization.  
ISOTHERMAL TITRATION CALORIMETRY (ITC) ANALYSIS 
Syntaxin1A, SNAP25C, SNAP25N and VAMP2-Δ60 were mixed together at a 
1:1.2:1.2:1.2 molar ratio and incubated at 4oC overnight to form the SNARE-Δ60 
complex. Before ITC experiments, SNARE-Δ60 and CPX variants (CPX48-134, wtCPX, 
scCPX, ncCPX) were purified by gel filtration using a HiLoad Superdex 75 column (GE 
Healthcare Life Sciences) and PBS (phosphate buffered saline, pH 7.4: 137 mM NaCl, 3 
mM KCl, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate monobasic) 
with 0.25 mM TCEP as the running buffer, respectively. Peak fractions were pooled and 
concentrated. CPX 48-134 was added into SNARE-Δ60 at about 1.5:1 molar ratio and 
incubate overnight at 4oC to form blocked SNARE-Δ60. CPX variants and blocked 
SNARE-Δ60 were then dialyzed in the same flask against 3 liters of PBS buffer with 0.25 
mM TCEP for 4 hours at 4oC and then dialyzed against another 3 liters of fresh PBS 
buffer with 0.25 mM TCEP overnight at 4oC. The concentrations of dialyzed proteins 
were determined by using the Thermo Scientific Pierce Bicinchoninic Acid (BCA) 
protein assay kit with BSA as the standard and/or Bradford assay. 
 ITC experiments were performed on a Microcal ITC200 instrument. Typically, 
about 200 µL of  blocked SNARE solution (10 to 30 µM) was loaded into the sample cell 
and about 40 µL of  CPX solution (200 to 600 µM) was loaded into the syringe. An 
initial 0.2 µL injection was followed by several injections of constant volume. 180-
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second equilibration time was used after each injection to ensure complete binding. The 
heat change from each injection was integrated, and then normalized by the moles of 
CPX in the injection. All ITC experiments were carried out at 37°C and at least twice. 
Microcal Origin ITC200 software package was used to analyze the titration calorimetric 
data and obtain the stoichiometric number (N), the molar binding enthalpy (ΔH), and the 
association constant (Ka). “One-set-of-sites” binding mode was used. The equilibrium 
dissociation constant (Kd), the binding free energy (ΔG), and the binding entropy (ΔS) 




               (11)  
!G = "RT lnKa          (12) 
!G = "RT lnKa          (13)    
Samples as used in the ITC experiments were re-analyzed by size exclusion 
chromatography using the HiLoad Superdex 75 column to control that VAMP-60 does 
not dissociate from the t-SNARE complex during the measurements. 
FRET ANALYSIS. 
Positions D193 on SNAP25 and Q38 or A31 on CPX (hCpx1 residues1-134 
carrying superclamp mutations D27L, E34F and R37A was used in all FRET 
experiments) were mutated into cysteines using the Stratagene QuikChange Kit. SNAP25 
D193C was labeled with the donor probe, Stilbene (4-acetamido-4’-((iodoacetyl)amino)-
stilbene-2,2’-disulfonic acid, disodium salt, Invitrogen) and either CPX Q38C or A31C 
was labeled with the acceptor Bimane (Monochlorobimane, Invitrogen). Stilbene has 
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improved solubility compared to the established FRET dye Pyrene, and in conjunction 
with Bimane, it can be used to measure small changes at small distances. The proteins 
were labeled using 10X molar excess of dye overnight at 4°C in 50 mM Tris Buffer, pH 
7.4, containing 150 mM NaCl, 10 % Glycerol and 1 mM TCEP. Following overnight 
incubation at 4°C, the excess dye was separated from the labeled proteins using a NAP 
desalting column (GE Healthcare). The labeling efficiency was calculated using ε335 = 
35,000 L m-1cm-1 for Stilbene and ε396 = 5,300 L m-1cm-1 for Bimane, and the protein 
concentration was measured by Bradford assay using BSA as the standard. Typically, the 
labeling efficiency was >90% for Stilbene-SNAP25 and ~75% for Bimane-CPX. The 
double-labeled CPX/SNARE complexes were assembled overnight at 4°C and purified 
by gel-filtration on a Superdex 75 (10/30, GE Healthcare) gel filtration column. All 
fluorescence data were obtained on a Perkin-Elmer LS55 luminescence spectrometer 
operating at 25°C. Excitation and emission slits of 5 nm were used in all measurements. 
Fluorescence emission spectra were measured over the range of 350-550 nm with the 
excitation wavelength set at 335 nm. Background fluorescence from the buffer was 
subtracted to calculate the reported fluorescence values. The donor probe concentration 
was adjusted to 2 µM in all samples. Fluorescence resonance energy transfer (FRET) was 
used to calculate the distance between the two fluorophores 56. According to the FRET 
theory, the efficiency of energy transfer (E) is related to the distance (R) between the two 
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R0, the distance at the transfer efficiency equals 50% is given by the following equation: 
R0 = 9.78 !103 ! 2""4QDJ( )
1/6
        (15) 
The spectral overlap integral (J) between the donor emission spectrum and acceptor 
absorbance spectrum was approximated by using the summation 
        (16)
 
Where, Fd(λ) and εA(λ) represent the fluorescence intensity of the donor and the molar 
extinction coefficient of the acceptor at the wavelength λ. The overlap integral was 
calculated to be 1.34 X 10-14. The quantum yield (Kd = 1Ka ) of the Stilbene-SNAP25 was 
calculated to be 0.19 using tryptophan in solution (!G = "RT lnKa= 0.14) as the reference58. 
Polarization studies of SNAP25 193-Stilbene, CPX38-Bimane and CPX31-Bimane in 
both full-length and truncated SNARE complexes gave anisotropy values around 0.1 
showing that the FRET probes have isotropic motion, so value of 2/3 was used for 
orientation factor (κ²). The refractive index of the medium (η) was measured to 1.358. 
Using these values, R0 for the Stilbene-Bimane FRET pair was calculated to be 27.5 Å.  
The energy transfer data were obtained by measuring the change in donor 
fluorescence (donor quenching) in the presence of the acceptor. The donor fluorescence 
intensity was measured in the absence (fd) and presence (fa) of acceptor. The efficiency of 
transfer (E) was calculated using the equation E = 1- fa/fd. Since the labeling efficiency 
was not 100%, the observed transfer efficiency (Eobs) was corrected for the acceptor 
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stoichiometry. The corrected efficiency (Ecor) is given as Ecor = Eobs/fa, where fa is the 
fraction of assembly with acceptor 56.  
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CHAPTER FOUR 	  
PREFACE 
  
 In the last paper, we demonstrated how the Complexin Accessory Helix is capable 
of clamping fusion; namely by extending away from the four-helix bundle.  We modeled 
that it binds in an intermolecular alternate four-helix bundle, preventing the zippering of 
the VAMP2, not of its own SNARE complex, but of its neighbors.  The next obvious 
question to answer is how this clamp is released.  
In this paper, we investigate the mechanism behind the unclamping of Complexin 
by Synaptotagmin and calcium.  Based on observations that the Complexin sticks out at a 
45° angle in the pre-fusion, clamped state (modeled by VAMP60) and runs alongside the 
SNARE complex in the post-fusion state (modeled by VAMP96), it is evident that certain 
residues in VAMP2 are responsible for bringing the Complexin Accessory helix closer to 
the SNARE complex.  By extending the VAMP2 by a few residues at a time, I was able 
to pinpoint a region of the VAMP (aspartates 64, 65, and 68) responsible for this switch 
in position.  
 In combination with Isothermal Titration Calorimetry (ITC) data, liposome fusion 
data, and cell-cell fusion data, my FRET data demonstrate that this aspartate patch is 
responsible for allowing Synaptotagmin to release the clamp.   
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Complexin clamps synaptic SNARE-mediated membrane fusion by creating and 
stabilizing a new intermediate state, in which the v-SNARE is only ~50% zippered.  The 
crystal structure of this clamped state reveals that the Complexin accessory helix extends 
away from the SNAREpin in an “open” conformation, binding another SNAREpin, and 
inhibiting its assembly to clamp fusion. In contrast, the accessory helix in the post-fusion 
complex parallels the SNARE complex in a “closed” conformation.  Here we use targeted 
mutations, FRET spectroscopy, and a functional assay that reconstitutes Ca2+-triggered 
exocytosis to test and confirm the hypothesis that the conformational switch from open to 
closed in Complexin is needed for Synaptotagmin-Ca2+ to trigger fusion. Triggering 
fusion requires the zippering of three key Asp residues located in a “switch” region (64-
68) of the v-SNARE. Conformational switching in Complexin is integral to clamp release 
and is likely triggered when its accessory helix is released from its trans-binding to the 
neighboring SNAREpin, allowing the v-SNARE to complete zippering and open a fusion 
pore. 
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INTRODUCTION 	  
SNARE proteins are the core machinery driving membrane fusion between cargo-
carrying vesicles and their target membranes1-4 as v-SNAREs (anchored in the vesicle 
membrane) zipper into a coiled-coil four helix bundle5 with cognate t-SNAREs (anchored 
in the target membrane). In neuronal synapses, the principal SNAREs responsible for 
neurotransmitter release are the v-SNARE, VAMP2, localized to the synaptic vesicle, and 
the t-SNARE, a binary complex of SNAP25 with Syntaxin1, localized to the pre-synaptic 
plasma membrane. VAMP2 and Syntaxin1 each contribute one helix to the coiled-coil, 
and SNAP25 contributes the other two. Fusion by the isolated synaptic SNAREs is rapid 
and spontaneous6 implying that in the synapse, additional protein machinery is needed to 
arrest exocytosis until the signal to secrete is provided by the entry of calcium ions. 
One such protein is the calcium- and SNARE-binding protein Synaptotagmin7,8, 
which is the immediate sensor for synchronous vesicle fusion9-11. The SNARE complex 
binding protein Complexin12,13 (CPX) is equally required for synaptic transmission, 
functioning both positively as an activator of fusion and negatively as a clamp, to prevent 
fusion prior to the calcium signal14-19. We established on energetic grounds how CPX can 
be both a clamp and an activator of SNAREpins in an accompanying manuscript20.  
In a second manuscript, we established the precise nature of the clamped state 
using X-ray crystallography together with confirmatory solution and functional studies21. 
To capture this intermediate, we used a SNARE complex containing a C-terminally 
truncated VAMP (termed VAMP2-60) to mimic the half-zippered v-SNARE that is 
trapped in the clamped state14,18,20,22-24. In the structure, CPX binds one partially-zippered 
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SNARE complex via its central helix (CPXcen, residues 48-75) while its accessory helix 
(CPXacc, residues 26-48) extends away from this SNARE complex at ~45° to bridge to a 
second SNAREpin, binding its C-terminal three helix bundle so as to sterically block that 
SNAREpin’s own v-SNARE from completing its zippering. As a result of repeating these 
trans-interactions, the clamped SNAREpins are cross-linked into a rigid zig-zag array21, 
which is itself topologically incompatible with the opening of a fusion pore.  
In this paper we address the question: how is fusion switched “on” from the 
clamped state?  A novel feature of the pre-fusion mimetic structure is that in the clamped 
state, CPXacc angles away from the SNAREpin to which its central helix is attached, a 
conformation that we refer to as “open” (Figure 28, cyan).  This differs markedly from 
that observed in the fully-zippered post-fusion structure, where the CPXacc nearly 
parallels the SNARE complex25,26 which we refer to as “closed” (Figure 28, light cyan). 
Taken together, the two structures suggest that CPXacc undergoes a dramatic re-
orientation as part of the mechanism (requiring calcium binding to Synaptotagmin) that 
switches fusion “on” from the clamped state. In this paper, we show that the switch from 
the open to closed state is a molecular switch required to activate fusion from the 
clamped state. We report that three closely clustered Aspartate residues (positions 64, 65, 
and 68) in the C-terminal half of VAMP2 (termed the “Asp switch region”) must zipper 
into t-SNARE for CPX to move its accessory helix from the open (clamped) to the closed 
(post-fusion) conformation. Mutating these residues inhibits activation of fusion from the 
clamped state by de-stabilizing the open conformation.   
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RESULTS 
ZIPPERING ONE TURN OF THE VAMP2 HELIX TRIGGERS COMPLEXIN TO 
SWITCH FROM THE OPEN TO THE CLOSED CONFORMATION 
We utilize here a Förster Resonance Energy Transfer (FRET) analysis with a 
Stilbene/Bimane donor/acceptor pair to monitor the conformational state of CPXacc in 
CPX-SNARE complexes21.  In this assay, residue 193 of SNAP25 is labeled with the 
donor dye (Stilbene), and the acceptor dye (Bimane) is attached at residue 38 of CPXacc 
(Figure 28). This pair was chosen because of its sensitivity to changes in separations in 
the range of interest. When CPXacc adopts the open conformation, the fluorescent probes 
are far apart, resulting in low FRET, but when CPXacc moves to the closed 
conformation, the FRET probes are in close proximity, resulting in a larger FRET signal. 
Distances obtained in solution from FRET analysis of VAMP2 constructs used in 
crystallization (VAMP2-60 or VAMP2) were in excellent agreement with the distances 
observed in the respective crystals (Table 5). 
This FRET assay allows us to readily distinguish the open conformation 
(complexes with VAMP2 truncated at residue 60) from the closed conformation 
(complexes in which the cytoplasmic domain of VAMP is nearly complete, truncated at 
residue 96) (Figure 29). To explore what happens in complexes with VAMP2 truncations 
in between these two extremes, we assembled full length CPX-SNARE complexes in 
which the VAMP2 C-terminus was progressively extended beyond residue 60 (VAMP2-
65, VAMP2-69, VAMP2-73 and VAMP2-77) to mimic the progressive zippering of the 
VAMP2 C-terminus.  
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Figure	  28:	  Superposition of the structures of the pre- and post-fusion CPX/SNARE complexes21,25, 
showing the FRET label positions.  Syntaxin1 (residues 190-250) is in yellow, SNAP 25 N-terminal 
SNARE motif (residues 10-74) is in lime, SNAP 25 C-terminal SNARE motif (residues 141-203) is in 
green and VAMP2 is in blue (residues 25-60 dark blue; residues 61-96 in light blue). The “switch” residues 
(D64, D65 and D68) are marked in red. The Complexin (residues 26-73) in the pre-fusion complex is in 
cyan, while in the post-fusion complex is in light cyan. The FRET label positions, residue 193 on SNAP25 
and 38 on Complexin, are marked in magenta. The sequence of the C-terminal hydrophobic layer of 
VAMP2 (residues 57-90) with the C-terminal truncations tested in this paper (denoted by the residue 
number) is also shown. The black arrow in the post-fusion structure references CPX residue 48, the 
demarcation line between CPXcen and CPXacc.	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Constructs Distance between SNAP25 D193 and CPX Q38 (Å) 
VAMP2 Deletions 
VAMP2-60 34 ± 1 Å 
VAMP2-65 33 ± 2 Å 
VAMP2-69 34 ± 1 Å 
VAMP2-73 21 ± 2 Å 
VAMP2-77 24 ± 1 Å 
VAMP2 and VAMP2 Mutants (Residues 1-96)  
VAMP2 20 ± 1 Å 
VAMP-4X 33 ± 1 Å 
VAMP-3xDA 32 ± 3 Å 
Measured in Crystal Structure  
Pre-fusion (VAMP2-60) 28 Å 
Post-fusion (VAMP2) 18 Å 
Table	  5:	  FRET	  distances	  were	  determined	  from	  quenching	  of	  donor	  fluorescence	  between	  SNAP25	  D193	  and	  CPX	  Q38	  in	  CPX-­‐SNARE	  complexes	  with	  VAMP2	  deletions	  and	  mutants.	  	  The	  distances	  measured	  in	  the	  pre-­‐fusion	  and	  post-­‐fusion	  crystal	  structures21,25	  	  are	  given	  for	  comparison.	  	  Standard	  deviations	  are	  reported	  from	  n	  =	  4-­‐6	  independent	  experiments	  and	  they	  reflect	  the	  reproducibility	  of	  the	  spectra	  rather	  than	  accuracy	  of	  the	  distance	  measurements. 	   	  




Figure	  29:	  FRET experiments with C-terminal truncations of VAMP2. Fluorescence emission spectra of 
Stilbene/Bimane labeled CPX/SNARE complexes containing VAMP2-60 (residues 25-60, orange), 
VAMP2-65 (residues 25-65, green), VAMP2-69 (residues 25-69, purple), VAMP2-73 (residues 25-73, 
blue), VAMP2-77 (residues 25-77, red), and VAMP2 (residues 1-96, olive). A representative emission 
spectrum of a Stilbene (Donor)-only CPX-SNARE complex is shown in black. The donor-only spectrum 
was identical in all CPX-SNARE complexes.	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The FRET spectra show that CPXacc adopts the open conformation in truncated 
CPX-SNARE complexes when the VAMP2 C-terminus was extended to the +2 
(VAMP2-65) or +3 (VAMP2-69) hydrophobic layers (Figure 29). In these complexes, 
we observe low FRET efficiency, and the distance between the probes as measured by 
quenching of the donor fluorescence, is consistent with the distances observed in the 
crystal structure of the CPX-SNARE-60 complex (Figure 29 & Table 5).  
In contrast, when the VAMP2 C-terminus was extended only about one turn of 
the helix further, to the +4 hydrophobic layer (VAMP2-73) or beyond (VAMP2-77), high 
FRET efficiency is observed, quantitatively corresponding to the closed conformation, in 
which CPXacc runs parallel to the SNARE complex (Figure 29). In these complexes, the 
distance between donor and acceptor probes calculated from the FRET spectra is 
consistent with distances observed in the post-fusion CPX-SNARE structure (Table 5).  
Remarkably, there is an all-or-none, discrete switch from open to closed 
conformation when one more turn of the helix is added between VAMP2 residues 69 and 
73, without hybrid spectra of the two states. This shows that zippering of VAMP2 to at 
least the +4 hydrophobic layer is required for the switch in CPX conformation, indicating 
that a discrete ‘switch region’ is located in this stretch of VAMP2.  Please note that the 
full-length “superclamp” CPX (scCPX) was used in these and later studies in this paper 
for consistency and direct comparability with the crystal structure which also employed 
mutations in the CPXacc (D27L, E34F, R37A) that increase binding to the t-SNARE.  
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AN ‘ASP SWITCH REGION’ IN THE CRITICAL REGION OF VAMP2 
THROWS THE SWITCH 
In the post-fusion structure25, CPX binds the SNARE complex in the groove 
between VAMP2 and Syntaxin1, and the CPXcen makes three distinct contacts with 
VAMP2. Two of these interactions, a hydrophobic contact with VAMP2 V50/L54 and a 
salt-bridge with VAMP2 D57 are found in both the pre-fusion, clamped CPX-SNARE 
complex21 and the post-fusion fully-zippered CPX-SNARE complex25 structures. 
We observed that a third, distinct contact region involving VAMP2 residues D64, 
D65 and D68 is present in the post-fusion complex only25 (Figure 30), because the 
VAMP C-terminus was truncated at residue 60 in the pre-fusion complex21. These three 
Asp residues are located within the +2 to +4 hydrophobic layers of VAMP2, which we 
identified (Figure 29) as minimal ‘switch region’ required to switch CPXacc from the 
open to the closed conformation. They form hydrogen bonds and salt bridges to CPXcen 
which serve to anchor the accessory helix parallel (but without making any contacts) to 
the four helix SNARE bundle in the closed, post-fusion conformation (Figure 30). 
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Figure	  30:	  Hydrogen bonding and salt bridge interactions between the switch Asp residues (D64, D65, 
and D68) with CPXcen helix in the post-fusion complex25.	  
  
 	   	   	   	  
164 
 
To test the hypothesis that these contacts are needed to stabilize the closed 
conformation, we mutated all three switch Aspartate residues to Alanines in an otherwise 
complete VAMP2 cytoplasmic domain (residues 1-96) containing all of the VAMP 
residues that assemble into the four helix SNARE bundle5, a construct referred to as 
VAMP-3xDA (VAMP2 with D64A/D65A/D68A mutations). As expected, VAMP-3xDA 
fully zippers into t-SNARE, as shown by resistance to cleavage by Tetanus and 
Botulinum-B neurotoxins (Figure 31) and the fact that VAMP-3xDA (when produced in 
a full-length form, containing its membrane anchor) retains its capacity to mediate fusion 
with its cognate synaptic t-SNARE in the liposome fusion assay (Figure 31). 
As predicted by our hypothesis, CPXacc adopts the open conformation in the 
fully-zippered CPX-SNARE-3xDA complex, and its FRET spectrum corresponds closely 
to those of the pre-fusion mimetics of CPX-SNARE in which the switch region of VAMP 
is physically removed (Figure 32 and Table 5, raw data in Figure 33). Mutating the 
individual switch Asp’s reveals that all three Asp residues are required for the full-
switching of the CPXacc, as mutation of any of the three Asp residues (VAMP2-D64A, 
VAMP2-D65A and VAMP2-D68A) destabilizes the closed conformation (Figure 32, 
raw data in Figure 34). Mutating residue 64 (VAMP2-D64A) has the maximum 
destabilizing effect, so it might act as the internal trigger for the switch (Figure 32).
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Figure	  31:	  VAMP2 is the natural substrate for both Botulism-B (BoNT-B) and Tetanus (TeNT) 
neurotoxin.  Neither toxin can bind nor cleave if the binding residues on VAMP2 (41-45 for TeNT and 63-
67 for BoNT-B) are zippered into t-SNARE1. The free VAMP-3xDA is readily cleaved by both the 
neurotoxins (left panel) but is fully protected from cleavage in the presence of t-SNARE and CPX (right 
panel). This shows that VAMP-3xDA can assemble into a stable CPX-SNARE complex.	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Figure	  32:	  Complexin adopts an open conformation in CPX-SNARE complexes containing either VAMP-
3xDA or VAMP-4X.  Donor fluorescence at 410 nm (normalized to a Donor-only sample) for 
Stilbene/Bimane labeled CPX-SNARE complexes containing VAMP2-D64A, VAMP2-D65A, VAMP2-
D68A, VAMP-3xDA, or VAMP-4X is shown.  (The raw fluorescence emission curves are shown in 
Figure 32 and 33.) The donor fluorescence (at 410 nm) for VAMP2-60 (“open”) and VAMP2 (“closed”) 
are shown for comparison. Averages and standard deviations for 3-4 independent experiments are shown. 	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Figure	  33:	  Zippering in of all three Asp residues (D64, D65, and D68) in the VAMP2 C-terminus into t-
SNARE is required for full switching of the CPXacc position. Fluorescence emission spectra of 
Stilbene/Bimane labeled CPX-SNARE complexes containing VAMP-3xDA (VAMP2 with D64A, D65A, 
& D68A mutations, red) and VAMP-4X (VAMP2 with mutations L70D, A74R, A81D, and L84D, blue) A 
representative emission spectrum of Stilbene (Donor)-only CPX-SNARE complex is shown in black. The 
donor fluorescence level at 410 nm for the pre-fusion (VAMP2-60) and the post-fusion (VAMP2) 
CPX/SNARE complexes are shown as reference (dashed lines).	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Figure	  34:	  Zippering in of all three Asp residues (D64, D65, and D68) in the VAMP2 C-terminus into t-
SNARE is required for full switching of the CPXacc position. Fluorescence emission spectra of 
Stilbene/Bimane labeled CPX-SNARE complexes containing VAMP2-D64A(red), VAMP2-D65A (green), 
and VAMP2-D68A (blue). A representative emission spectrum of Stilbene (Donor)-only CPX-SNARE 
complex is shown in black. The donor fluorescence level at 410 nm for the pre-fusion (VAMP2-60) and the 
post-fusion (VAMP2) CPX/SNARE complexes are shown as reference (dashed lines).	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As predicted by our hypothesis, CPXacc adopts the open conformation in the 
fully-zippered CPX-SNARE-3xDA complex, and its FRET spectrum corresponds closely 
to those of the pre-fusion mimetics of CPX-SNARE in which the switch region of VAMP 
is physically removed (Figure 32 and Table 5, raw data in Figure 33). Mutating the 
individual switch Asp’s reveals that all three Asp residues are required for the full-
switching of the CPXacc, as mutation of any of the three Asp residues (VAMP2-D64A, 
VAMP2-D65A and VAMP2-D68A) destabilizes the closed conformation (Figure 32, 
raw data in Figure 34). Mutating residue 64 (VAMP2-D64A) has the maximum 
destabilizing effect, so it might act as the internal trigger for the switch (Figure 32).  
ZIPPERING OF THE ASP SWITCH RESIDUES IS REQUIRED TO SWITCH 
THE CPXACC POSITION 
So far, we know that CPXacc is trapped in the open conformation when the 
switch Asp’s are absent from VAMP (due either to point mutations or deletion).  What 
about when the switch Asp’s are present but not able to zipper? This would correspond 
more closely to what occurs physiologically before these residues have zippered. To 
mimic this state, we employed a VAMP construct in which the normal switch Asp’s are 
present but carry point mutations in the C-terminal (membrane-proximal) region of 
VAMP that prevent full zippering. 
Specifically, we used the entire VAMP2 cytoplasmic domain (residues 1-96) and 
introduced mutations in its C-terminal half (L70D, A74R, A81D & L84D; termed 
VAMP-4X) that prevent assembly of this region with Syntaxin1 and SNAP25 and 
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eliminate fusion activity (Figure 29). However, the N-terminal half of VAMP-4X still 
zippers because VAMP-4X forms stable complexes with t-SNARE and CPX (Figure 35). 
The FRET spectrum of the CPX-SNARE-4X complex (Figure 32 and Table 5, raw data 
in Figure 33) was nearly identical to the open conformation observed in CPX-SNARE 
complex with VAMP-60 or when the switch Asp’s were mutated or deleted by 
truncations. (Figure 32 and Table 5) 
Importantly, this experiment establishes that the mere presence of the VAMP2 
residues D64, D65 and D68 is not sufficient for switching: they must also be zippered 
with the t-SNARE in the helical bundle in order to throw the switch from open to closed. 
This strongly suggests that zippering of the switch region of the v-SNARE (i.e., 
progression of fusion beyond the clamped state) and movement of CPXacc from its open 
to its closed arrangement are thermodynamically coupled i.e. one cannot occur without 
the other.  
This also could explain why CPXacc adopts an open conformation in the CPX-
VAMP-69 complex (Figure 29 and Table 5). Even though the key residues required for 
the switch (D64, D65 and D68) are present in this complex, they are at the end of the 
truncated VAMP2, and they may not be properly zippered into the t-SNARE. Extending 
the VAMP2 C-terminus one rung on the helix to the next hydrophobic layer (VAMP2-
73) could then allow the switch region to stably zipper into the t-SNARE, and switch 
CPXacc to the closed conformation (Figure 29 and Table 5). 
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Figure	  35:	  VAMP4X forms stable SNARE complexes. A representatitive Superdex 75 elution profile for 
SNARE4X (blue) and CPX-SNARE4X (red) complex are shown. Inset: Coomassie stained SDS-PAGE gel 
of the SNARE4X and CPX-SNARE-4X complex peak is shown.	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THERMODYNAMICS OF THE COMPLEXIN CONFORMATIONAL SWITCH 
We used Isothermal Titration Calorimetry (ITC) to determine the energetics of the 
contributions of the switch Asp residues to the open-to-closed conformational switch. To 
this effect, we compared the thermodynamics of binding of CPX to SNARE complexes 
assembled with either VAMP2 or VAMP-3xDA (Figure 36). Complexin binds the 
VAMP2 SNARE complex with 1:1 stoichiometry and high affinity (Kd = 83 nM). 
Mutating the switch Asp residues (VAMP-3xDA) does not alter the binding 
stoichiometry, but results in 8-fold decrease in the binding affinity (Kd = 670 nM) 
(Figure 36 and Table 6), corresponding to a free energy difference of -1.3 kCal/mole. 
The enthalpy of the interaction of CPX with the SNARE complex was greatly reduced, -
15 kCal/mole for the VAMP-3xDA SNARE complex as compared to -37.5 kCal/mole for 
the wild-type VAMP2 sequence. So the difference in the enthalpy (ΔΔH = -22.5 
kCal/mole), is mainly from the interaction of CPXcen with the switch Asp residues on 
VAMP2. 
In control experiment, when we blocked the CPXcen binding site on VAMP-
3xDA SNARE complex by pre-binding CPXcen (residues 48-134), we see no further 
interaction with CPX (Figure 36). This shows that the interaction of CPX with the 
SNARE-3xDA complex is mediated solely by CPXcen. In addition, this confirms that 
SNARE-3xDA complex is fully-zippered since the additional binding site for CPXacc 
i.e., the C-terminal t-SNARE groove is not available for binding. 
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Figure	  36:	  Interaction of CPX central helix with Asp residues (D64, D65, D68) on VAMP2 provides 
thermodynamic driving force for the switch. Calorimetric titrations of scCPX (residues 1-134 carrying 
superclamp mutations D27L, E34F, R37A, scCPX) into assembled SNARE complexes containing t-
SNAREs and either VAMP2 (blue triangles), VAMP2-3xDA (red squares), or VAMP-3xDA with the 
CPXcen binding site blocked by CPX 48-13 (black circles). The solid lines represent the best fit to the 
corresponding data points using a nonlinear least squares fit with a one-set-of-sites model. The results of 
the fits are given in Table 6. All experiments were performed in triplicate at 37oC, and a representative 
thermogram is shown. 	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0.95 ± 0.01 
 
83 ± 17 
 
-37.5 ± 0.7 
 
-88.6 ± 2.7 
 






0.99 ± 0.04 
 
670 ± 90 
 
-15.0 ± 1.0 
 
-20.1 ± 3.6 
 






0.98 ± 0.01 
 
620 ± 110 
 
-14.0 ± 1.1 
 
-16.6 ± 3.8 
 
-8.8 ± 0.1 
Table	  6:	  Thermodynamic parameters of CPX binding to SNAREs measured by Isothermal Titration 
Calorimetry. Superclamp CPX (scCPX, residues 1-134 carrying superclamp mutation D27L, E34F, R37A, 
scCPX) or CPX48-134 were titrated into assembled SNARE complexes containing VAMP2 (residues 1-96) 
or VAMP-3xDA (residues 1-96 with mutations D64A, D65A, & D68A). The thermodynamic parameters 
were calculated by nonlinear least squares fit with a one-set-of-sites model from the binding isotherms 
shown in Figure 36. Average and standard deviations of a minimum of three independent experiments are 
shown. 
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THE CONFORMATIONAL SWITCH IN COMPLEXIN OCCURS WHEN 
CALCIUM BINDS TO SYNAPTOTAGMIN TO TRIGGER FUSION 
To the extent that the open-to-closed conformational switch in CPX is needed to 
activate fusion from the clamped state, locking CPXacc in the open state will prevent 
activation of fusion and result in a persistent clamped state, which should inhibit 
activation of fusion by Synaptotagmin and calcium ions.  
To test this, we utilized the ‘flipped’ SNARE system in which cells expressing 
either VAMP2 or Syntaxin1-SNAP25 proteins on their surface are mixed and the rate of 
cell-to-cell fusion is scored using light microscopy3. In this system, fusion occurs 
spontaneously, unless CPX is added either as an exogenous pure protein or by 
endogenous gene expression and secretion. In the presence of CPX, fusion is blocked 
when the SNAREs are approximately half-zippered, as judged by the pattern of 
Botulinum and Tetanus neurotoxin resistance14. When Synaptotagmin is either added 
back to the medium (cytoplasmic domain only) or endogenously expressed as a flipped 
protein, fusion is then re-activated upon addition of Ca2+ ions14.  The physiological 
relevance of this minimal system was established by several criteria14. For example, 
mutations in Synaptotagmin that alter calcium sensitivity in mice, correspondingly alter 
sensitivity in this reconstituted system, toxin sensitivity in the clamped state reproduces 
the pattern found at the neuromuscular junction and most recently, super-clamp mutations 
of CPXacc that increase clamping potency in neurons 27also do so in this in vitro system15 
We tested the activation of fusion mediated by VAMP-3xDA (VAMP2 with 
D64A/65A/68A) from the clamped state by Synaptotagmin and calcium and confirmed 
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the prediction that clamp release would be impaired when the v-SNARE lacked the 
switch Asp residues (Figure 37, VAMP-3xDA, green bar). The limited extent of 
activation that was observed with VAMP-3xDA and wild-type CPX was similar to the 
essentially permanent clamped state that results when  wild-type SNAREs are frozen with 
super-clamp CPX (Figure 37, scCPX, green bar). In the latter case, the open state is 
stabilized by stronger binding of CPXacc to trans-t-SNARE, whereas in the former case 
it is the closed state that is de-stabilized by weaker binding of CPXcen to the SNARE 
bundle due to switch Asp mutations. As expected, mutating individual Asp residues in 
the switch region partially compromised activation in a manner reflecting their relative 
contributions to stabilizing the closed conformation measured by FRET (Figure 32). 
As a control, we tested VAMP-3xDA in the absence of any CPX to confirm that it 
is intrinsically fusion competent (Figure 37, blue bars). Furthermore, we found that the 
clamping of fusion by wild-type CPX was identical for cells expressing VAMP2 or 
VAMP-3xDA (Figure 37, red bars). Because the mutations of the switch Asp’s lock 
CPXacc in the open state, the fact that we see functional clamping in VAMP-3xDA is 
consistent and confirmatory that the accessory helix exerts clamping in the open 
conformation21. 
To further characterize the VAMP-3xDA mutation, we analyzed the kinetics of 
the activation of fusion by Synaptotagmin and calcium from the clamped state. We found 
the overall kinetics of clamp release was similar in cells expressing VAMP-3xDA or 
VAMP2 (Figure 38), but the extent of activation of fusion by Ca2+-Synaptotagmin was 
limited at all time points (Figure 38). These activation curves have the same calcium 
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requirement (EC50 ~ 100 µM, Figure 39) indicating that the effect is mainly due to an 
intrinsic property of the VAMP-3xDA mutation rather an impairment in Synaptotagmin. 
These results clearly demonstrate that the conformational switch in CPX position is 
essential for Synaptotagmin to trigger fusion upon arrival of the Ca2+ signal.  
To further characterize the VAMP-3xDA mutation, we analyzed the kinetics of 
the activation of fusion by Synaptotagmin and calcium from the clamped state. We found 
the overall kinetics of clamp release was similar in cells expressing VAMP-3xDA or 
VAMP2 (Figure 38), but the extent of activation of fusion by Ca2+-Synaptotagmin was 
limited at all time points (Figure 38). These activation curves have the same calcium 
requirement (EC50 ~ 100 µM, Figure 39) indicating that the effect is mainly due to an 
intrinsic property of the VAMP-3xDA mutation rather an impairment in Synaptotagmin. 
These results clearly demonstrate that the conformational switch in CPX position is 
essential for Synaptotagmin to trigger fusion upon arrival of the Ca2+ signal.  
DISCUSSION 	  
The data presented establish that a region near the middle of the VAMP2 SNARE 
motif must be folded with the t-SNARE in order for CPX to assume the closed 
conformation. This positions the key Aspartate residues (D64, D65, D68) to correctly 
interact with the CPX central helix (Figure 30), driving CPX from its open into its closed 
conformation. The data also reveal that accessing the closed conformation is not required 
for clamping, but it is required for calcium-bound Synaptotagmin to release the clamp.  
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Figure	  37:	  The switch in CPXacc position is necessary for Synaptotagmin/Ca2+ to trigger fusion. 
Clamping of SNARE-mediated fusion by CPX and the reversal of the clamp by Synaptotagmin/Ca2+ in 
wild-type VAMP2, VAMP2-D64A, VAMP2-D65A and VAMP-3xDA as measured in a cell-cell fusion 
assay. The effect of the superclamp CPX (scCPX; CPX D27L, E34F, R37A) on wild-type VAMP2 is 
shown for comparison.	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Figure	  38:	  Kinetics of the reversal of the CPX clamp by Syanptotagmin/Ca2+. The cell fusion recovery 
was carried out at 1mM free Ca2+ and the samples were fixed at the indicated time point after the addition 
of Ca2+. 	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Figure	  39:	  Ca2+/Synaptotagmin sensitivity of the VAMP-3xDA mutation. Calcium titration experiment 
using cells expressing VAMP2 or VAMP3x-DA. 5 min after the addition of PI-PLC/EGTA, the free Ca2+ 
concentration was raised to the indicated concentration (ranging from 5 to 5000µM) and the cells were 
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Clamp release entails removing CPXacc from its trans-t-SNARE binding site so 
that the trans-SNAREpin can complete zippering and thereby fuse the bilayers. In light of 
the network of interactions constituting the zig-zag array21 (Figure 40), it is hard to 
imagine how this could occur as an isolated event.  For example, if any one CPX in the 
array (example, the CPX emanating from SNAREpin 3 in Figure 40) were to flip from 
open to closed, in so doing, it would necessarily pull its CPXacc out of the binding 
pocket of its trans-SNAREpin across the midline of the array (number 2), where it had up 
until then been bound (Figure 40).  But, in actuality this could not happen unless the 
switch region of the v-SNARE within SNAREpin 3 had somehow zippered up to create 
the binding site needed to anchor its emanating CPXacc. However, this in turn, is 
prohibited by yet another CPXacc (emanating from SNAREpin 4) which plugs the path 
of the v-SNARE within SNAREpin 3 (Figure 40). This suggests that the zippering of the 
VAMP2 c-terminus and the conformational switch in CPX must both occur in the short 
interval corresponding to clamp release, probably concomitantly. In essence, the zig-zag 
array seems designed either to remain as it is or to disassemble in a nearly simultaneous 
cascade, ideally suited for the synchronous activation of synaptic transmission. How 
could this be triggered? 
The structure suggests an appealingly simple hypothesis. Removing any 
individual SNAREpin from the zig-zag entails breaking contacts with two other 
SNAREpins, one before and the other after it in the array (SNAREpin 3 in Figure 40). 
This fracture will almost always break the CPXacc bonds rather than the CPXcen bonds, 
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because the former (ΔG = -6.8 kCal/mole) are much weaker than the latter (ΔG = -9.1 
kCal/mole)21. When this occurs, the cascade outlined in the last paragraph could be 
spontaneously triggered (see discussion below), and the SNAREpins located across the 
midline of the zig-zag would zipper away from each other to form the fusion pore and 
release neurotransmitter.   
If our speculative hypothesis that fusion is triggered by perturbing a single 
SNAREpin in the array is correct, the activation energy that needs to be provided to 
enable this triggered fusion will be the energy required to disrupt the two CPXacc-t-
SNARE binding sites in which that SNAREpin is engaged, totaling ~14 kCal/mole 
(corresponding to ~20 kBT) 21. The source of this energy must be from Synaptotagmin 
binding to calcium, the event that triggers release from the clamped state8. When 
Synaptotagmin binds calcium, it undergoes a conformational change28 and as a result, 
~21 kCal/mole of free energy (corresponding to ~33 kBT) is made available to do work 
beyond that which is needed for the conformational change itself29 as the sum of the 
individual ΔG values for sites 1-3 in C2A/B, excluding site 4 because it binds calcium 
well above the physiological range). In addition, the calcium-Synaptotagmin complex 
binds acidic phospholipid-containing bilayers with a Keq of ~2 µM29, corresponding to 
~12 kBT. The total energy potentially available to perturb the zig-zag array when a single 
Synaptotagmin binds its complement of calcium ions is thus ~45 kBT, greatly exceeding 
the energy needed to remove its attached SNAREpin (~ 20 kBT in our model). 
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Figure	   40:	  Perturbation of a single SNARE complex in the zig-zag array should be sufficient to rapidly 
disassemble the clamp in response to neuronal stimulus. A small perturbation of one CPX-SNARE 
complex in the clamped zig-zag array would eliminate interactions with both of its neighbors in the array. 
For example, a disruption of complex 3 would eliminate interaction with complexes 2 and 4. So, if one set 
of the CPXacc-SNAREpin interactions were to be perturbed by Syaptotagmin/Ca2+, then VAMP2 could 
zipper up, and the entire zig-zag array would disassemble very rapidly, releasing the clamp and triggering 
fusion.	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Of course, it is not known how much of Ca2+-Synaptotagmin’s energy resource is 
usefully funneled into disrupting the array, but these considerations make it tenable to 
suggest that activation of a single Synaptotagmin molecule (by its bound complement of 
calcium ions) could be sufficient to dislodge its single bound SNAREpin, and that this in 
turn is sufficient to trigger synchronous release of a quantum of neurotransmitter. 
Twisting, pulling, or pushing on a SNAREpin with sufficient (~20 kBT) energy will 
remove it from the array, as is illustrated by SNAREpin 3 in Figure 40. Though the 
structural details are still missing, it is easy to imagine how a conformational change in 
Synaptotagmin (perhaps driven by stabilization of its compact conformation when it 
binds calcium28,30,31 could perturb an attached SNAREpin in this manner.  In addition, 
Synaptotagmin is expected to rapidly adhere to the acidic phospholipids (mainly PS and 
PIP2) in the nearby synaptic vesicle and/or plasma membrane cytoplasmic leaflets,7,8,32-34 
which would also be expected to perturb an attached SNAREpin out of planarity in the 
array.  But, it is important to point out that lipid binding alone (~12 kBT)29 does not 
appear to be sufficient to activate fusion (~20 kBT) though it may well make an important 
contribution. The N-terminal domain of CPX (residues 1-25, which precede the CPXacc) 
also contributes to the activation process in vivo35, but is not needed in our minimal cell-
cell fusion system15. Also, recent data suggests that Ca2+ alone could perturb the CPX-
SNARE complexes even in the absence of Synaptotagmin, in certain cases36. 
Neurotransmitters can be released within as little as 200 µsec after calcium ions 
enter the nerve terminal37. Can activation in our single Synaptotagmin-SNAREpin 
hypothesis keep pace with this?  The results from SFA show that the open and closed 
 	   	   	   	  
185
states in the zig-zag array of SNAREpins and CPX (in the absence of Synaptotagmin) are 
separated by an activation energy barrier of ≥ 30 kBT20. The rate of spontaneous fusion 
from the CPX-clamped state in the flipped SNARE fusion assay, toff ~ 1 hour14 indicates 
an energy barrier also close to 30 kBT (based on the well-established Kramers-Evans 
relationship between activation energy and dissociation rate38, which predicts toff for a 30 
kBT barrier will be between 0.3 to 3 hours). Starting with the ~ 30 kBT value for the 
spontaneous activation energy barrier from the array, removing a single SNAREpin (by 
Ca2+-Synaptotagmin or any other means) is predicted to reduce the activation energy 
barrier by ~20 kBT. The remaining barrier of ~10 kBT will be transited38 in 2-20 µsec, in 
no way limiting for the overall time required to release the first quanta of transmitter. 
Put differently, the activation energy of ~10 kBT for unbinding CPXacc in the 
clamped array implies that single CPXacc dissociation events will occur spontaneously 
every 2-20 µsec, but these will fruitlessly snap back into the array and not result in 
spontaneous fusion. The activation barrier for spontaneous fusion from the clamped state 
of ~30 kBT suggests that it is only when three such contacts are broken (presumably in 
neighboring SNAREpins) that the fusion pore can successfully opens with high 
probability.  In our model, perturbation by Ca2+-Synaptotagmin serves to remove two of 
these three accessory helices, and when the third spontaneously dissociates (2-20 µsec) 
the fusion pore can now open. The lifetime of the Ca2+-Synaptotagmin complex, whose 
lower limit is set by the duration of the rise in local calcium concentration, is far longer 
than this, and so the third and final CPXacc will have many chances to dissociate while 
calcium is still bound.  
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METHODS 	  
PLASMID CONSTRUCTS 
The constructs used in this study are are pET28a oligohistidine-Thrombin-
syntaxin1A (containing rSyntaxin1a residues 191-253), pET28a oligohistidine-MBP-
Thrombin-SNAP25N (containing hSNAP25A residues 7-82 and a C-terminal 
tryptophan), pET28a oligohistidine-Thrombin-SNAP25C (containing hSNAP25A 
residues 141-203) and pET15b oligohistidine-Complexin (containing hcomplexin1 
residues 1-134 with the following “super clamp” mutations: D27L, E34F, R37A).The 
VAMP2 c-terminal truncations were pET28a-oligohistidine-SUMO-VAMP2-60 
(hVAMP2 residues 25-60) -VAMP2-65 (hVAMP2 residues 25-65); -VAMP-69 
(hVAMP2 residues 25-69); -VAMP-73 (hVAMP2 residues 25-73); -VAMP-77 
(hVAMP2 residues 25-77).   VAMP-4X and VAMP-3xDA were generated by 
introducing L70D/A74R/A81D/L84D and D64A/D65A/D68A mutation, respectively into 
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pET15b-oligohistidine-Thrombin-VAMP2 (human VAMP2 residues 1-96) using 
QuickChange mutagenesis Kit (Stratagene). VAMP-D64A; -D65A and -D68A were also 
generated in the same fashion. In these constructs, ‘Thrombin’ and ‘SUMO’ refer to the 
protease cleavage site. 
PROTEIN EXPRESSION AND PURIFICATION 
All constructs were expressed and purified as described previously21. Briefly, 
recombinant fusion proteins were expressed in E.coli BL21 (DE3) cells by induction with 
1 mM IPTG for 3 h at 37°C.  Cells were harvested and re-suspended in Breaking Buffer 
(50mM Tris, 150 mM NaCl, 1 mM TCEP, pH 7.4) supplemented with protease inhibitors 
(SIGMAFAST cocktail, EDTA-free, SIGMA), then lysed using a cell disruptor 
(Avestin). A cleared lysate obtained by centrifugation was incubated for 3-4 hours with 
Ni-NTA-agarose (Qiagen) resin. The suspension was transferred into a polypropylene 
column and washed with 25 column volumes of Wash buffer (50mM Tris, 150 mM 
NaCl, 1 mM TCEP, pH 7.4), followed by 10 column volume of Wash buffer 
supplemented with 50mM Imidazole. For all v- and t-SNARE proteins, the beads were 
re-suspended in wash buffer and incubated with Thrombin or SUMO protease, as 
appropriate for the cleavage site, overnight at 4°C to remove the tags. For complexin, the 
protein was eluted from the beads using 400mM Imidazole in Wash buffer and excess 
Imidazole was removed by dialysis against wash buffer or by NAP25 desalting column 
(GE Healthcare) equilibrated with the wash buffer. In most cases, the proteins were pure 
and required no further clean-up. In few cases that required further clean up, the proteins 
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were subjected to size exclusion chromatography on a Hi-Load Superdex 75 (16/60, GE 
Healthcare) column equilibrated with Wash buffer.  
FRET ANALYSIS 
Positions D193 on SNAP25C and Q38 on CPX were mutated into cysteines using 
the Stratagene QuikChange Kit. SNAP25 D193C was labeled with the donor probe, 
Stilbene (4-acetamido-4’-((iodoacetyl)amino)-stilbene-2,2’-disulfonic  acid, disodium 
salt,  Invitrogen) and  CPX  Q38C was labeled with the acceptor Bimane 
(Monochlorobimane, Invitrogen) as described previously21. The double-labeled CPX-
SNARE complexes were assembled overnight at 4°C and purified by gel-filtration on a 
Superdex 75 gel filtration column. All fluorescence data were obtained on a Perkin-Elmer 
LS55 luminescence spectrometer operating at 25°C and the conditions are similar to 
those used previously21. FRET distances were calculated as described previously using a 
R0 for the Stilbene-Bimane FRET pair to be 27.5 Å21 
TOXIN ACCESSIBILITY ASSAY 
VAMP2 is the natural substrate for neurotoxins, Botulinum-B and Tetanus39, but 
is protected from cleavage by the neurotoxins, if zippered into t-SNARE. To test the 
accessibility of VAMP-3xDA to the neurotoxins, 5µM of either free VAMP-3xDA or 
CPX-SNARE-3xDA complex were incubated with the neurotoxins at 1:20 toxin:protein 
ratio in a Tris Buffer pH 7.4 150 mM NaCl containing 100 µM Zn2+ at 37°C for 2 hours 
and was analyzed by SDS PAGE/Coomassie Stain. Botulinum-B and Tetanus light chains 
were purified as described previously14 
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LIPOSOME FUSION ASSAY 
VAMP2 and t-SNARE proteins were incorporated in liposome at 1:400 
protein:lipid ratio and liposome fusion assay was carried out as described 
previously4,40,41. Briefly, 45 µl unlabeled t-SNARE liposomes was mixed with 5 µl 
labeled v-SNARE liposomes in a 96-well plate and fusion was followed by measuring the 
increase in NBD ﬂuorescence at 538 nm (excitation 460 nm) every 2 min at 37°C. At the 
end of the 2 hr reaction, 10 ml of 2.5% dodecyl-maltoside was added to the liposomes 
and the fusion is plotted as the percentage of the maximal NBD fluorescence40. 
CELL-CELL FUSION ASSAY 
The flipped SNARE cell-cell fusion assay was performed essentially as described 
before3,14,15,42. In brief, HeLa cell lines were transiently transfected with flipped VAMP2 
(WT or 3xDA), DsRed2-NES and either with or without CPX mutants and 
Synaptotagmin as indicated (v-cells). After one day, transfected v-cells were seeded onto 
glass coverslips containing cells stably co-expressing flipped syntaxin1, flipped SNAP-25 
and CFP-NLS (t-cells). The following day, cells were fixed with 4% paraformaldehyde 
directly or after treatment with recovery solution (1 U/ml Phosphatidylinositol Specific 
Phospholipase-C, 20 µg/ml laminin, with or without 1.8 mM EGTA), washed and 
mounted with Prolong Antifade Gold mounting medium (Molecular Probes). Confocal 
images were acquired on a Zeiss 510-Meta confocal microscope and processed using 
Adobe Photoshop software. Kinetics of the reversal of the CPX clamp by 
Syanptotagmin/Ca2+ was essentially carried out as described, wherein 5 minutes after the 
addition of PI-PLC/EGTA, the free Ca2+ concentration raised to 1mM the samples were 
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fixed at 5 minute interval between 5 and 30 min after the addition the addition of Ca2+. 
For the calcium sensitivity experiment, free Ca2+  was raised to the indicated 
concentration (ranging from 5 µM to 5000 µM) and the cells were incubated at 37°C for 
30 min before fixing the cells for quantitation. 
ISOTHERMAL TITRATION CALORIMETRY (ITC) ANALYSIS 
SNARE complex and blocked-SNARE complex for ITC measurements were 
assembled and purified as described previously21 using PBS (phosphate buffered saline, 
pH 7.4, 10 mM sodium phosphate dibasic, 2 mM potassium phosphate monobasic,137 
mM NaCl, 3 mM KCl) with 0.25mM TCEP. ITC experiments were performed on a 
Microcal ITC200 instrument. Typically, about 200 µL of SNARE complex solution (~10 
µM) was loaded into the sample cell and about 40 µL of CPX solution (~200 µM) was 
loaded into the syringe. An initial 0.2 µL injection was followed by several injections of 
constant volume. 180-second equilibration time was used after each injection to ensure 
complete binding. The heat change from each injection was integrated, and then 
normalized by the moles of CPX in the injection. “One-set-of-sites” binding mode was 
used to analyze the titration calorimetric data and obtain the stoichiometric number (N), 
the molar binding enthalpy (ΔH), and the association constant (Ka) using Microcal Origin 
ITC200 software package. The affinity constant (Kd), the binding free energy (ΔG), and 
the binding entropy (ΔS) were calculated using the thermodynamic equations:  
 Kd = 1/Ka          (17)  
ΔG= -RT lnKa and          (18) 
ΔG = ΔH-TΔS .         (19) 
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CHAPTER FIVE 	  
CONCLUSIONS 	  
In the previous three chapters, I demonstrated that I succeeded in developing a 
new FRET pair (Chapter 2) and using it to validate the novel crystal structure put forth in 
Kümmel, et al (Chapter 3).  Further, I explored the nature of the trans-SNARE complex 
in depth and developed a model for clamping (Chapter 3).  I also looked at the 
mechanism of release of the Complexin clamp and identified three VAMP2 residues 
required for the unclamping of Complexin by Synaptotagmin (Chapter 4). 
To review, the crystal structure of a trans-SNARE/Complexin mimetic was 
obtained by truncating the v-SNARE to residue 60, the +1 layer, and making use of the 
superclamping Complexin mutant used in Giraudo et al.[1].  The recently solved crystal 
structure is similar to that of the post-fusion crystal structure [2, 3]in many 
ways.  Namely, in both of the structures, both the t- and present v-SNARE residues align 
nearly perfectly.  Further, the Complexin molecule still binds via its Central Helix in an 
antiparallel fashion.  This internal consistency serves as a control to validate that the 
novel part of the structure is at least in the realm of possibility.  
The most significant difference between the two crystal structures is a large 
displacement of the Accessory Helix from a position nearly alongside the SNAREpin to 
one at a 45° angle, pointing away from the SNAREs.  In the crystal, the Accessory Helix 
is stabilized by an interaction with the C-terminal region of the t-SNAREs of a 
neighboring complex.  While this is precisely why the crystal was stable and ordered 
enough to form, the veracity of this structure is called into question, both because the 
 	   	   	   	  
198 
VAMP2 truncation mutant and the superclamping Complexin were used and neither is 
what occurs in biology. The main concern is that this positioning of Complexin is due to 
an artifact of crystallization both because the VAMP2 C-terminus is absent and the 
Complexin has a higher propensity to bind in the clamped state than wild-type.  I used 
FRET to address these concerns; if the positioning of the Complexin is solely a function 
of crystal interactions, the Accessory Helix would not maintain its 45° angle in solution, 
where the low concentration and high entropy would not “force” the stabilizing 
Accessory Helix/t-SNARE interaction found in the crystal structure. 
In my FRET studies, I developed a novel FRET pair based on the previously used 
Pyrene and Bimane [4]and calculated the pair’s spectroscopic parameters.  Then, I used 
this FRET pair to determine whether the Accessory Helix was indeed sticking out into 
space in solution.  I placed the donor dye Stilbene on SNAP25 at position 193 and the 
acceptor dye Bimane at two positions on Complexin, 38 and 31.  By using labeled 
versions of the same constructs as were used in the crystal structure (including the 
truncated VAMP2), I was able to validate that the Accessory Helix does, in fact, extend 
away from the four helix bundle in solution.  I also established that the 45° angle was not 
due to the truncation of VAMP2’s C-terminus as one might predict. Rather, a full length 
mutant in which critical C-terminal hydrophobic layer residues are mutated to charged 
residues (VAMP-4X) demonstrated that the Complexin sticks away from the four helix 
bundle despite the presence of the VAMP2 C-terminus; rather, it is because the VAMP2 
C-terminus is not zippered into the four helix bundle.  The mere presence of the C-
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terminal residues of VAMP2 is not sufficient to result in a Complexin angled in, rather 
than angled out configuration.   
Because I performed bulk FRET, it was possible that instead of seeing the 
Accessory Helix positioned at 45°, I could have been observing a time or population 
average of various populations of Accessory Helix positions both closer to and further 
away from the four helix bundle.  I was able to discern that the 45° angle configuration is 
a biologically relevant state for the Accessory Helix, and not simply a time average of the 
entire space sampled by an unstructured patch of Complexin, by introducing a helix-
breaking motif between the Central and the Accessory Helices.  This helix-breaking 
motif caused the Accessory Helix to lose its structure as demonstrated by CD. Without 
the helix-breaking motif, the Accessory Helix was rigidly positioned, and not freely 
moving into space. On the other hand, in Complexin containing the helix-breaking motif, 
the acceptor is further away than that of Complexin lacking the helix breaker.  This 
means that the positioning of the Accessory Helix is, in fact, real and not an average of 
two disparate states in solution.  Thus, the crystal structure solved represents reality and 
is not an artifact of crystallization.   
Because the Accessory Helix sticks away from the SNARE complex at such a 
large angle, the intramolecular clamping model posited in by Giraudo et al.[1] cannot 
occur.  Instead, it is the Accessory Helix must clamp via another model.  A hint at this 
new model is gleaned by examining the formula unit of the recent crystal structure.  In 
this formula unit, a zig-zag array is formed, wherein the Accessory Helix of one 
SNARE/Complexin complex forms an “alternate four helix bundle” with the C-terminal 
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region of a second SNARE/Complexin complex.  This suggests that the clamp might be 
formed intermolecularly, with any given SNAREpin unable to fully zipper because its v-
SNARE is prevented from zippering by its neighbor’s Complexin Accessory Helix.  This 
model then further suggests several lines of evidence of how clamping could occur. First, 
fusion is prevented because the Accessory Helix physically blocks the area where the v-
SNARE would normally zipper.  Fusion is also blocked because bringing the 
SNAREpins closer at their zippering ends would cause steric clash in the zig-zag 
model.  Further, fusion is blocked because the linker regions of Syntaxin1 and VAMP2 
are on different sides of the zig-zag midline, which interferes with complete 
zippering.  And lastly, fusion is blocked because of the zig-zag array due to the fact the 
SNAREpins are locked in place and unable to move into a circular configuration.   
Subsequently I set out to discover the region of VAMP2 responsible for allowing 
the Accessory Helix to be released from the 45° angle position down to the parallel to the 
SNAREpin position.  I did so by progressively increasing the length of the VAMP2 
construct from its initial length (residues 26-60) to the full length cytoplasmic domain, 
(residues 26-96). I discovered that the presence of the VAMP2 region between residues 
69 and 73 is required for this transition.  An examination of the crystal structure [2] 
reveals three patches of binding interactions between VAMP2 and Complexin. The first 
patch is a hydrophobic contact between VAMP2’s V50 and L54 and CPX’s M62 and I66. 
The second is a salt bridge between VAMP2’s D67 and CPX’s R63 and R59. The third is 
a grouping of salt bridge and hydrogen bonding interactions between residues Y52 and 
R48 on Complexin and aspartates 64, 65, and 68 on VAMP2.  
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I hypothesized that these three residues were responsible for the positioning of the 
Accessory Helix with respect to the four helix bundle. To test this, I mutated the 
aspartates to alanines.  This triple mutation, VAMP-3xDA prevents the Accessory Helix 
from coming down to the SNAREpin, while the individual single mutations yield 
intermediate profiles.  I demonstrated that these three residues are important for the 
release of the clamp by Synaptotagmin in cell-cell fusion assays.  In fact, this mutant 
shares a phenotype with that of the superclamping Complexin in these cell-cell fusion 
assays[1], suggesting two separate processes are involved in clamp removal: first, the 
Accessory Helix must be able to be removed from the t-SNARE C-terminal region so 
VAMP2 can zipper in, and second, the VAMP2 must be capable of receiving the 
Accessory Helix upon its release from the neighboring SNAREpin, preventing the 
Accessory Helix from re-interacting with its neighbor.   
This provides an insight into the mechanism of release of the Complexin clamp 
by Synaptotagmin.  Once Synaptotagmin removes one SNAREpin/Complexin complex 
from the zig-zag structure, its t-SNAREs’ C-terminal region is no longer blocked by a 
neighboring Accessory Helix, which means the VAMP2 can zipper into the C-terminal 
region of the Four Helix Bundle.  Further, the associated Complexin’s Accessory Helix is 
then able to move from its clamped 45° position to the unclamped position, running 
alongside the four helix bundle. This prevents the Accessory Helix from blocking its 
neighbor on its other side, enabling the neighbor’s VAMP2 to zipper up as well.  Because 
the Accessory Helix is tethered to its own SNAREpin, it is prevented from reassociating 
with a neighboring complex.  This rapid cascade of clamp release enables the fast and 
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synchronous fusion associated with calcium-dependent synaptic fusion which occurs in 
vivo.  
FUTURE DIRECTIONS 	  
    While this model addresses several experimental observations that have arisen with 
Complexin, it fails to directly address others.  It has been proposed that CPX facilitates 
fusion by keeping the SNAREs in a primed, fusogenic state[5-7].  The model we propose 
posits that the SNAREs are primed for fusion, in keeping with this prediction.  Our model 
also addresses the biochemical predictions made in the Giraudo et al paper[1]; namely, 
the residues found to be in the interacting face between CPX’s Accessory Helix and the t-
SNARE groove include the residues Giraudo et al [1]mutated to make the superclamping 
mutation. 
Not addressed in our model, however, is the functionality of either the N-terminal 
or C-terminal domains of Complexin.  It is easy to imagine, however, that the N-terminal 
domain is capable of stabilizing the SNAREs in the context of a zig-zag array as 
suggested by[8, 9], perhaps acting as a glue to hold the N-terminal domain of VAMP into 
the acceptor t-SNARE complex.  Also our model leaves room for the C-terminal domain 
to interact with the membrane as predicted by[8, 10]. This C-terminal membrane 
interaction may help recruit Complexin to the site of SNARE action helping to increase 
its local concentration. But for now, neither of these domains is described in the model.   
To learn more about these domains, one might choose to use FRET.  For example, 
by retaining the donor dye on position 193 in the C-terminal helix of SNAP25, and 
moving the acceptor positions around in the N- and C-terminal regions of Complexin, a 
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distance profile could be obtained for each domain, suggesting the positioning of these 
regions with respect to the SNARE four helix bundle.  Cross-linking or NMR 
experiments could further confirm the proximity of the N- or C-terminal domains to 
various parts of the SNAREs or membranes. 
The issue of greatest importance which is not explicitly proven in the previous 
chapters is the veracity of the zig-zag array in vivo.  While it is very clear that the 
Complexin Accessory Helix sticks away from the four helix bundle, and while no other 
mechanism of clamping seems feasible, it is irresponsible to claim with 100% certainty 
that the zig-zag array is definitely what happens in a cell.  To assay this, membranes will 
be required, not only to order the molecules in solution, but also to increase their local 
concentration.  In the lab, we are currently trying to achieve this using nanodiscs[11].  
Also, it is likely that single-molecule assays will also be required. One other option to 
monitor the association of two SNAREpins through a bridging Complexin molecule is to 
label one population of SNARE/Complexin complexes with VAMP60 or VAMP-4X with 
donor dye and another population of SNARE-only complexes with VAMP60 or VAMP-
4X with acceptor dye and look for FRET.  If FRET occurs, one SNARE complex must 
interact with a second SNARE complex, and the molecule bringing them together must 
be Complexin.   
Our proposed model also does not directly address why Complexin appears to 
have different functions in different animals.  Perhaps this is because of different 
Accessory Helix binding interfaces in different species(ref), but it could also be a 
combination of differences in N- and C-terminal region sequences.  For example, the 
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Drosophila melanogaster Accessory Helix contains more hydrophobic residues than the 
mouse version(ref); because of this, it likely acts as a better clamp.  Another difference in 
Complexin Accessory Helices between species occurs with C. elegans, wherein the 
Accessory Helix is disrupted by a helix-breaking proline residue[12].  And yet, somehow 
this domain remains inhibitory towards fusion in the nematode, potentially via some 
other method than what occurs in mammals.  The Accessory Helix question can best be 
addressed by crystallography, to examine how these different species’ Complexins 
interact with the SNAREpins. 
Another aspect our model does not explain is precisely how the zig-zag array is 
disrupted beyond hypothesizing that Synaptotagmin can provide enough energy to disrupt 
the array.  Many further experiments must be performed to assay how and with which 
residues Synaptotagmin binds the trans-SNARE complex.  For example, FRET 
experiments can be performed to examine the interaction interface.  Because 
Synaptotagmin requires membranes for function(ref), these experiments should be 
performed both with and without membranes to determine whether Synaptotagmin’s 
ability to bind the trans-SNARE is dependent on its membrane-binding capability.  Bulk 
FRET studies could likely determine the interaction interface, but single molecule studies 
would be required to visualize Synaptotagmin disrupt the zipper.  Furthermore, as 
Synaptotagmin is the calcium sensor, experiments should be carried out in both the 
presence and absence of Ca2+ to determine the effect of calcium-binding on the 
positioning of Synaptotagmin’s C2A and C2B domains.  Another question is: does 
Synaptotagmin bind the trans-SNARE complex better when Complexin is present, 
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suggesting it binds after Complexin does, as Yang et al. suggest[13], does Synaptotagmin 
bind the trans-SNARE complex without Complexin, suggesting Synaptotagmin binds 
first, as Sorensen et al. [14] propose or that they compete, as Tang et al.[15] suggest?  
While the structural predictions made in the Giraudo et al. paper[1] are addressed 
by the papers contained in this thesis in vitro, real in vivo data are lacking besides the 
cell-cell fusion assay.  To address this, experiments both in stable nerve cell or other 
secretory cell lines as well as in live animals must be performed using these 
mutations.  Currently, the only in vivo experiments addressing the superclamping 
mutations were recently published by the Südhof lab (Yang et al 2010), and they validate 
that the superclamping mutations effectively inhibit fusion events in cortical mammalian 
neurons. Further studies must be done on the superclamping mutations in organisms to 
obtain actual phenotypes. And now that the 3xDA mutations have been discovered, they 
must be examined in both cultured cells and live animals for a phenotype, as well.  It is 
very clear that much more work remains to be done to understand the intricacies of 
clamping and release within synaptic release, and to answer all of the questions regarding 
the interplay among Complexin, Synaptotagmin, calcium, membranes, and 
SNAREs.  The work presented in this thesis helps to explain both the clamping and 
release from a mechanistic perspective.   
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